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ABSTRACT 
Development and Evaluation of Approaches for Quantitative Optical 
Molecular Imaging of Neoplasia 
by 
Kelsey Jane Rosbach 
This thesis develops and evaluates three approaches for quantitative molecularly-
targeted optical imaging of neoplasia. The first approach focuses on widefield imaging 
of biomarkers near the tissue surface for early detection applications; this approach is 
demonstrated in freshly resected oral tissue. Most oral cancers are not detected until the 
disease has spread, but topical application of targeted imaging agents allows rapid 
visualization of biomarker expression, giving real-time, objective information. 
Epidermal growth factor receptor (EGFR) expression was quantified in patient samples 
using fluorescent epidermal growth factor. Dysplasia (n=4) and cancer (n=13) had an 
average 2.3-fold and 3.8-fold increase in signal compared to normal tissue. EGFR 
expression was assessed along with metabolic activity using a fluorescent glucose analog, 
2-NBDG, in 9 patient samples. A classification algorithm using quantitative image 
features resulted in an area under the curve (AU C) of 0.83, though the main advantage of 
this technique may be to understand spatial heterogeneity of biomarker expression and 
how this correlates with disease. 
The next approach focuses on high-resolution optical imaging through a needle to 
detect metastases in lymphoid tissue for clinical staging applications; this approach is 
demonstrated in resected lymph nodes from breast cancer patients. These patients often 
require removal of nodes, but an optical imaging strategy using topical application of 
imaging agents in vivo may classify nodes as normal or metastatic, thus reducing 
unnecessary removal of normal nodes and improving metastasis detection. Proflavine, a 
nuclear dye, was topically applied to 43 nodes. A classification algorithm developed 
from quantitative image features distinguished normal lymphoid tissue from metastases 
with an AUC of0.84. 
Because optical imaging is depth limited, the final approach combines high-
resolution optical imaging with magnetic resonance imaging (MRI) for multimodal 
evaluation of deep tissue. An imaging agent functional in both optical and MRI was 
developed by co-loading fluorescent EGFR antibodies and gadolinium-based contrast 
agents in silicon discs. These discs accumulate in tumors, resulting in localized delivery 
of imaging agents. 
The research presented here can be applied to understanding tumor biology and 
biomarker heterogeneity, with the future clinical goal of improving identification of 
disease and determination of appropriate therapy for cancer patients. 
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CHAPTER 1: INTRODUCTION 
1.1 Project Overview 
This thesis develops and evaluates approaches for quantitative molecularly-
targeted optical imaging of dysplasia and cancer. The first approach focuses on widefield 
optical imaging of biomarkers near the tissue surface for early detection applications. 
The next approach focuses on high-resolution optical imaging through a needle to detect 
metastases in lymphoid tissue for clinical staging applications. The fmal approach 
combines high-resolution optical imaging with magnetic resonance imaging (MRI) for 
multimodal evaluation of tumors far below the tissue surface. 
The problem of cancer cannot be overstated: the World Health Organization 
(WHO) reports that cancer killed 7.6 million people in 2005, accounting for over 13% of 
total deaths worldwide and making it a major global health problem [1]. This thesis 
demonstrates applications of optical imaging with molecularly-targeted contrast agents in 
clinical samples from two types of tissue: first in oral mucosa from oral squamous cell 
carcinoma patients, and next in lymph nodes from breast cancer patients. Development 
of a multimodal imaging agent is described, and future clinical applications for cancer are 
suggested but are not yet performed in this exploratory study. 
1.2 Specific Aims 
The primary goal of my research was to apply molecularly-targeted imaging 
agents onto relevant clinical samples in order to develop and evaluate quantitative optical 
imaging approaches for neoplasia. The quantitative information obtained from 
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fluorescence images indicated the presence of known biomarkers of dysplasia and cancer, 
which could then be assessed for correlations between biomarker expression and the 
presence of disease or examined to determine the heterogeneity of biomarker expression. 
To demonstrate how optical imaging with targeted contrast agents may be used as a tool 
for studying biomarker expression and predicting the presence of disease, the following 
specific aims were set: 
(1) Demonstrate the potential of non-invasive topical delivery of an epidermal 
growth factor-Alexa 647 (EGF-Alexa 647) conjugate to image changes in epidermal 
growth factor receptor (EGFR) expression associated with oral neoplasia. In this aim, I 
performed a series of pre-clinical analyses to evaluate the optical contrast achieved 
following topical delivery of EGF-Alexa 647 in a variety of model systems, including 
cells, three dimensional tissue cultures, and intact human tissue specimens using 
widefield and high-resolution fluorescence imaging. Images were collected from 
seventeen different oral cancer patients: eight pairs of normal and abnormal biopsies and 
nine resected tumors were examined. The studies in this aim demonstrated that the EGF-
dye conjugate could be uniformly delivered throughout the oral epithelium with a 
penetration depth exceeding 500 microns and incubation time of less than 30 minutes. 
Following EGF-Alexa 647 incubation, the presence of oral neoplasia was associated with 
a 1.5-6.9 fold increase in fluorescence contrast as compared to grossly normal mucosa 
from the same patient with both widefield and high-resolution fluorescence imaging. 
(2) Map out detailed biomarker expression of both EGFR and metabolic activity 
in freshly resected human specimens of oral cancer and dysplasia to demonstrate 
concurrent visualization of multiple biomarkers, examine the heterogeneity of their 
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expression, and predict the presence of disease. In this aim, I topically applied both EGF-
Alexa 647 and 2-NBDG (a fluorescent glucose analog used as a metabolic activity 
indicator) to the epithelial surface of nine patients and used widefield imaging to capture 
the molecularly-targeted fluorescent signal. 286 total 50 x 50 pixel-sized regions with a 
uniform histopathologic diagnosis ranging from normal, mild dysplasia, moderate 
dysplasia, and severe dysplasia to cancer were quantitatively analyzed to extract 
statistical features used to train a linear discriminant classification algorithm. When the 
developed algorithm was tested on the same set of regions, it had an area under the curve 
(AUC) of 0.83. When the classification algorithm was applied using a higher cut-off for 
posterior probability, regions of disease were predicted that contained mostly neoplasia 
either 99% (using a posterior probability range of 0.80-1.00) or 95% (using a posterior 
probability range of 0.60-0. 79) of the time. This aim demonstrated a proof of concept of 
using information from multiple biomarkers to predict the presence of disease, and also 
described the potential use of understanding biomarker heterogeneity in both basic cancer 
research and in clinical management of cancer patients. 
(3) Perform a pilot study to evaluate the potential of high-resolution fiber optic 
microscopy (HRFM) to identify lymph node metastases in breast cancer patients. In this 
aim, I collected 43 lymph nodes from 14 consenting breast cancer patients and topically 
applied proflavine dye to lymph nodes ex vivo to allow visualization of nuclei. 242 
images were collected at 105 sites with confirmed histopathologic diagnosis. Quantitative 
statistical features were calculated from images, assessed with one-way ANOV A, and 
were used to develop a classification algorithm with the goal of objectively 
discriminating between normal and metastatic tissue. A classification algorithm using 
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mean image intensity and skewness achieved sensitivity of79% (27/34) and specificity of 
77% (55171). This aim demonstrated the technical feasibility and diagnostic potential of 
HRFM with fluorescent contrast in the ex vivo evaluation of lymph nodes from breast 
cancer patients. 
( 4) Investigate the combination of previously developed molecularly-targeted 
optical imaging agents with contrast agents of other imaging modalities. In this aim, I 
co-loaded EGFR antibody conjugated to Alexa Fluor 647 along with a variety of 
gadolinium-based contrast agents (Gd-CAs) into small pores in silicon discs. Sequential 
loading of first the Gd-CA followed by the antibody-dye conjugate resulted in a 
multimodal contrast agent that can be detected by both optical and magnetic resonance 
imaging (MRI). A fluorometer was used to quantify the efficiency of antibody-dye 
loading for several combinations of type of Gd-CA and silicon disc pore size. The 
combination with the highest loading efficiency and consistency was co-loading 
Magnevist®, a clinically approved Gd-CA, with the antibody-dye conjugate into silicon 
discs with a 10 nanometer pore size. This aim characterized the combination of a 
molecularly-targeted optical imaging agent with a gadolinium-based MRI contrast agent 
that may eventually be used in multimodal imaging applications in cancer research. 
1.3 Dissertation Overview 
Chapters two, three and four focus on the optical imaging approach of using 
widefield imaging with molecularly-targeted contrast agents to look at surface biomarker 
expression for early detection applications in oral cancer. The second chapter provides 
background on the problem of oral cancer; the majority of this text appeared in my thesis 
proposal, but has been updated to include current literature in the field as well. This 
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chapter provides motivation and background for the studies applied to oral cancer, the 
application that represents the bulk of my research focus. The third chapter includes a 
paper that I published in Neoplasia in 2009 describing the topical application of EGF-
Alexa 647 to paired biopsies and intact tissue specimens from oral cancer patients. The 
fourth chapter demonstrates optical molecular imaging of multiple biomarkers in 
epithelial neoplasia, specifically, EGFR expression and metabolic activity in oral mucosa. 
This chapter will form the basis of a future publication. The fifth chapter shifts focus to 
an optical imaging approach that uses high-resolution imaging through a needle for the 
application of clinical staging. It includes a paper that I published in Biomedical Optics 
Express in 2010 describing a pilot study to investigate the potential of high-resolution 
imaging of proflavine fluorescence to classify lymph nodes from breast cancer patients as 
either normal lymphoid tissue or metastatic tissue. The sixth chapter describes an 
imaging approach that could be applied in a deep tissue tumor setting through the 
development and characterization of a multimodal contrast agent for both MRI and high-
resolution optical imaging. The combination of modalities helps address the depth 
limitations of optical imaging. The seventh chapter provides summary, conclusions and 
future directions for the dissertation. 
6 
CHAPTER2:BACKGROUND:ORALCANCER 
2.1 Motivation and Significance 
With over 300,000 new cases being diagnosed every year, cancer of the oral 
cavity is a major global health problem [2, 3]. Surveillance Epidemiology and End 
Results (SEER) data estimated that in 2010 in the United States alone, 36,540 new cases 
of oral cancer were diagnosed, and 7,880 deaths occurred due to the disease [4]. 
However, the majority of new oral cancer cases occur in developing countries, especially 
in India and other areas of Southeast Asia. In these regions, oral cancer comprises over 
one-third of all new malignancies and is one of the most common forms of cancer [ 5, 6]. 
The WHO estimates that oral cancer is the world's eighth most common malignancy [7]. 
The incidence of oral cancer has been increasing in parts of the world, and has remained 
fairly constant in the United States and Europe [8, 9]. 
In the United States, the average 5-year survival rate for all oral cancer patients 
has remained steady for the past 50 years at approximately 50%. However, expected 
survival is largely dependant on the stage at which the cancer is diagnosed and treated 
[10]. As shown in Figure 2-1, patients with locally confined disease have a much higher 
survival rate than patients with regional spread or distant metastases. Unfortunately, 
since early symptoms are rare, over 60% of patients with oral cancer are not diagnosed 
until their disease is in stage III or IV, meaning the cancer is no longer locally confined 
[ 11]. Once the disease has spread, much more aggressive treatment is required, resulting 
in associated morbidities that affect normal function and quality of life. The surgery 
required to remove a large, advanced tumor may interfere with speech, mastication, or 
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deglutition, and can also affect physical appearance. Survival rates are even lower in the 
developing world, and the associated morbidities of treatment cannot be dealt with as 
effectively. Therefore, earlier detection of oral cancer has the potential to dramatically 
improve survival and quality of life for all patients. 
100% 
90% 
80% 
70% 
60% 
50% 
40% 
30% 
20% 
10% 
0% 
Local Regional Distant 
Figure 2-1. 5-year survival rates of oral cancer patients in the United States based on 
extent of tumor spread show the impact of early detection on prognosis. 
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2.2 Oral Cavity 
2.2.1 Normal Histology 
The oral cavity has a stratified squamous epithelium lining [12]. This mucosa is 
composed of tightly packed epithelial cells that differ morphologically and molecularly 
depending on the depth beneath the surface. The deepest cells on the basement 
membrane layer are undifferentiated and are constantly proliferating. The more 
superficial cells, however, are specialized according to the function and type of the 
mucosa in a particular area. The oral cavity has three main types of mucosa: masticatory 
mucosa, lining mucosa, and specialized mucosa. 
Masticatory mucosa is present on the gingiva and hard palate. It has either a 
keratinized or para-keratinized stratified squamous epithelium, resulting in nuclei that are 
either no longer present or highly pyknotic in cells at the superficial layer. There are four 
distinct layers of the masticatory mucosa. The stratum basale is the deepest, basal layer 
that contains undifferentiated cells responsible for cell proliferation. These basal cells are 
small with prominent nuclei and are cubiodal or columnar in shape. New cells produced 
in this layer are pushed up to create subsequent layers of mucosa. Stratum spinosum is 
the next layer, consisting of larger cells that are polyhedron-shaped. More keratin 
filaments are present in this layer, and membrane-coating granules (MCG) appear near 
the top of this layer. More MCGs are present in the next layer, the stratum granulosum. 
This layer is characterized by flat cells with small nuclei and densely packed keratin 
filaments. MCGs fuse with cell membranes and release their contents into the cells at the 
top of this layer, forming the boundary between the stratum granulosum and the surface 
keratinized layer. The density of the keratin filaments and the thickening of the cell 
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membrane at the surface create a thick, tough layer that reduces the permeability of the 
masticatory mucosa. 
Lining mucosa is found on the lips, cheeks, alveolar mucosal surface, floor of 
mouth, inferior surfaces of the tongue, and soft palate. It covers muscle, bone, and 
glands, and is generally non-keratinized. It consists of three layers. The deepest layer 
again is the stratum basale, a single layer of cells resting on the basal lamina that is 
responsible for cell proliferation. The stratum spinosum is similar to that of masticatory 
mucosa and is several cells thick. The stratum superficiale of lining mucosa displays 
some cell membrane thickening, keratin filaments, and MCG fusion associated with 
masticatory mucosa, but is more permeable. 
Specialized mucosa is associated with the sensation of taste and so is only present 
on the dorsal surface of the tongue. It contains papillae and taste buds responsible for 
generating the chemical sensation of taste. 
2.2.2 Precancerous Pathology 
While normal, healthy oral mucosa appears pink, red or white regions that appear 
may have the potential for malignant transformation. Leukoplakia (white patches) and 
erythroplakia (red patches) are clinical diagnoses of grossly abnormal tissue that often 
indicate dysplasia, a precursor to cancer [7, 13]. Dysplasia is a transitional state between 
benign growth and malignancy, but does not always progress to cancer. It is 
characterized by cytological changes including variability in nuclear size and shape, 
increased nuclear staining by dyes, increased ratio of nuclear versus cytoplasmic size, 
increased mitotic activity, and lack of the cytoplasmic features associated with normal 
differentiated cells of the tissue [14]. In dysplastic epithelium, the relative numbers of 
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the cell types associated with the epithelial layers are no longer observed, drastically 
affecting overall tissue architecture. These changes generally begin near the basement 
membrane and can eventually affect the tissue throughout the entire thickness of the 
epithelium. The severity of dysplasia is determined by the level of the epithelium 
affected. In mild dysplasia, only the lower one-third of the epithelium contains abnormal 
cells, while in moderate dysplasia, the lower two-thirds of the epithelium displays pre-
malignant changes. Severe dysplasia occurs when the entire epithelium contains cells 
displaying abnormal cytologic features. If a region of severe dysplasia experiences 
malignant transformation throughout the entire epithelium, but has not invaded beneath 
the basement membrane, the lesion is defined as carcinoma-in-situ. 
2.2.3 Cancerous Pathology 
Once the abnormal cells are no longer confmed within the epithelium, the lesion 
has progressed to invasive carcinoma, or cancer [14]. Malignant cells are able to invade 
into the space beneath the basement membrane, where they continue to proliferate locally 
and may also spread to other regions of the body. 90-95% of carcinomas found in the 
oral cavity are squamous cell carcinomas, meaning they are tumors that arise from cells 
of the epithelium [ 15]. The most common sites for squamous cell carcinomas are the 
tongue (30%), lip (17%), and floor ofmouth (14%) [16]. These tumors are usually well 
or moderately well differentiated, meaning they retain some similarity both 
architecturally and cytologically to the tissue of origin. Cells of these tumors are 
commonly arranged in broad sheets and large nests [14]. Cells of well-differentiated 
tumors form keratin, often leading to masses of keratin called keratin pearls. Well-
differentiated tumors have a better prognosis than poorly differentiated tumors, which no 
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longer resemble the tissue of origin. Poorly differentiated tumors do not form keratin 
pearls, and have a high nuclear to cytoplasmic ratio. 
2.2.4 Benign Oral Lesions 
In addition to the precancerous and cancerous states described above, there are 
many benign oral mucosal abnormalities. These include lichen planus, candidiasis, 
submucosal fibrosis, and frictional hyperkeratosis among others. Often these conditions 
look similar under white light to premalignant lesions, and can cause inflammation at the 
site of the lesion. These can be confounding factors for detection and diagnosis of oral 
dysplasia and cancer. 
2.3 Current Detection Strategies 
2.3.1 Conventional Oral Examination 
The standard method for oral cancer screening has long been dentists or 
physicians performing a conventional oral examination. This exam is performed under 
normal white light and consists of visual inspection of the oral cavity by a healthcare 
professional, followed by palpation of suspicious lesions. While some published studies 
indicate a high degree of sensitivity, specificity, and positive predictive value of the 
conventional oral exam [17-21], other publications suggest that this type of examination 
has limited value [22, 23]. The expertise of the healthcare professional plays a major role 
in the value of a conventional oral exam as a screening tool: two pilot studies showed that 
general dentists had a 71-7 4% sensitivity of detecting relevant oral mucosal lesions as 
compared to a specialist's diagnosis [24, 25]. In developing countries with less available 
medical expertise, a conventional oral exam may be even less effective. 
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The shortcomings of a conventional oral exam stem from the fact that 5-15% of 
the general population have oral mucosal abnormalities; only a small fraction of these are 
actually malignant [26-28]. The oral lesions that have the most relevance to oral cancer 
are leukoplakia and erythroplakia, clinical diagnoses that refer to white or red patches, 
respectively. Approximately 10-15% of patients who present with leukoplakia will have 
their lesions histologically categorized as mild or moderate dysplasia, and about 5% will 
receive a diagnosis of severe dysplasia or carcinoma in situ [ 13]. The remaining 
leukoplakia patients have a slightly increased risk of developing a malignancy at that site, 
and should be monitored [29, 30]. Oral erythroplakia is much more rare, but is usually 
histologically diagnosed as severe dysplasia, carcinoma in situ, or invasive carcinoma [7]. 
A clinician is unable, however, to definitively differentiate between stages of disease with 
a conventional oral exam alone, and a biopsy must be taken. The final shortcoming of 
the oral exam is that it may be unable to detect malignancies underlying normal mucosa. 
One study found that 36% of patients with a new head and neck squamous cell carcinoma 
showed histologic evidence of dysplasia or microinvasive cancer in clinically normal 
mucosa from the corresponding contra-lateral anatomic site [31]. 
2.3.2 Gold Standard of Diagnosis 
The biopsy is considered the gold standard of diagnosis for oral cancer. This 
method requires the removal of a portion of the suspicious lesion, followed by fixation, 
slicing, hematoxylin and eosin (H&E) staining, and diagnosis by a pathologist [32]. This 
process can take about a week, is invasive for the patient, and requires major resources 
including equipment and professional expertise [30, 33]. It presents an inconvenience, 
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expense, and delay of treatment in developed countries, and is not feasible on a large 
scale in the developing world. 
2.3.3 Detection Aids 
Other methods to aid in detection of oral cancer have been investigated, including 
brush cytology, toluidine blue staining, and light-based detection systems. Brush 
cytology uses an approach similar to the Papanicolaou smear: a stiff brush scrapes 
epithelial cells from the suspicious region and these cells are stained and examined for 
features such as increased nuclear to cytoplasmic ratio [34]. This is a less invasive, less 
expensive method of examining lesions with low cancer risk [31, 35-38]. However, it 
still requires laboratory equipment and expert cytologists. Overall, oral cytology has 
demonstrated a limited sensitivity and specificity, and a high occurrence of false negative 
results [39]. 
Toluidine blue is a vital dye that has been used in vivo to stain nucleic acids and 
reveal abnormal tissue. It has been used in the oral cavity for decades as a screening tool 
or as an adjunct to a visual exam [ 40-42]. However, low specificity has prevented 
toluidine blue from becoming a standard screening tool in the United States [43-45]. 
Light-based detection is another strategy that is being employed to assist in the 
detection of oral cancer. Two commercially available systems, the ViziLite Plus and the 
MicroLux DL, use tissue reflectance imaging to enhance oral lesion detection [ 46-50]. 
The patient's mouth is rinsed with acetic acid and then visually examined using a blue-
white light source [11]. While normal epithelium appears slightly bluish under 
illumination, abnormal epithelium experiences distinct aceto-whitening due to cellular 
dehydration and compaction of the nucleus. However, studies suggest that while the 
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sensitivity of these systems may be high, the specificity and positive predictive value is 
low, preventing this tool from becoming widely accepted in clinical practice [51, 52]. 
Several benign conditions such as leukoedema and frictional keratosis also experience 
aceto-whitening [ 46]. 
Other light-based detection systems use autofluorescence rather than reflectance 
to detect abnormal tissue. Cellular alterations that occur due to malignant transformation 
can alter the concentration of naturally occurring fluorophores in tissue, thus resulting in 
a change in autofluorescence of the region. Both imaging and spectroscopy devices have 
been shown to distinguish between normal and malignant tissue [53-55]. However, 
imaging systems may be more practical for screening for oral cancer because a much 
larger area can be observed at one time as opposed to the small region that can be 
examined at a single time with the optical fibers used in spectroscopy [56]. The 
VELscope is a commercially available device that uses narrow-emission tissue 
fluorescence to visually detect abnormal lesions [57-59]. The tissue is excited at 400-460 
nm, and normal tissue appears pale green when viewed through the narrow-band filter 
provided with the instrument. Abnormal tissue, however, displays a loss of 
autofluorescence and appears dark next to the normal tissue. One of the first studies 
using this instrument (published in 2006) reported extremely high values of sensitivity 
and specificity for the VELscope, but in this study all the lesions were also recognized by 
the conventional oral exam under white light [58]. In a 2010 study of 156 patients, the 
reported VELscope sensitivity was 50% and specificity was 38.9% [51]. In this study, 
the VELscope again did not identify any abnormal sites that were not detected under 
white light inspection alone. In a 2011 analysis, A wan et al. reported a VELscope 
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sensitivity of 84.1% and specificity of 15.3% after examining a set of 126 patients with 
premalignant or benign oral abnormalities [60]. The high prevalence of confounding 
factors and the low specificity of the VELscope prevent this device from distinguishing 
between low-risk and high-risk lesions in the oral cavity, limiting its use as a screening 
tool for oral cancer. 
2.4 Contrast Agents 
Epithelial tissue contains various sources of endogenous contrast that arise from 
the morphological and molecular features of the tissue. These features can be altered 
along the path of cancerous progression, and so measuring these features has been 
important to delineate stages along that progression. As described previously, reflectance 
imaging can be used to observe changes in tissue architecture as an indication of 
dysplasia or cancer. Fluorescence imaging and spectroscopy can measure loss of 
autofluorescence that occurs in abnormal oral tissue. These inherent changes in 
reflectance and fluorescence arise as neoplasia alters cellular characteristics such as inter-
nuclear spacing and fluorophore concentration. These endogenous sources of contrast 
can be used to distinguish between normal and abnormal tissue. 
While endogenous contrast has been useful, the optical detection of cancer can be 
enhanced with exogenous contrast agents that also highlight morphological and 
molecular changes within tissue. Exogenous contrast agents have a much brighter optical 
signature and so are more sensitive to small changes in tissue as compared to endogenous 
contrast. This may allow for earlier detection and characterization of abnormal oral 
lesions. In addition, exogenous contrast agents are able to target specific molecules of 
interest that cannot be detected with endogenous contrast. 
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The exogenous contrast agents that will be used in the studies reported in this 
thesis are described below. The advantages of fluorescent contrast agents include the 
small size of the fluorophore, the bright optical signal, the choice of excitation and 
emission wavelengths, and the ability to detect the signal with low cost light sources such 
as light emitting diodes (LEDs) [61, 62]. Fluorescent dyes are very small, and so are able 
to penetrate through multiple layers of tissue. This relative ease of delivery makes them 
well suited to stain both cells and tissue. 
2.4.1 Agents Targeted to the Epidermal Growth Factor Receptor 
The human epidermal growth factor (EGF) is a small peptide consisting of 53 
amino acids, and is about 6 kDa in size. It is the natural ligand to the epidermal growth 
factor receptor (EGFR) on the extracellular surface of cells. Although EGFR is present 
in normal proliferating cells [63], the receptor is over-expressed in 50-98% of all oral 
squamous cell carcinomas, and is associated with early tumorigenesis, making it an 
excellent biomarker for oral cancer [64-69]. Cancer cells up-regulate this growth 
receptor so that they can achieve self-sufficiency in growth signals, which is one of the 
hallmarks of cancer [70]. Tumor EGFR levels have been shown to correlate tumor size 
and clinical stage [64, 65, 68], and can serve as a prognostic indicator for overall disease-
free survival [66]. 
EGF-Alexa 647 consists of an Alexa Fluor 647 carboxylic ester dye (Invitrogen, 
CA) conjugated to human EGF peptide (Calbiochem, MA) at the peptide's primary 
amine groups. This conjugate is purified using size exclusion chromatography and 
dialysis to remove any free dye from the labeled peptide. The Alexa Fluor dye excites at 
647 nm and emits at 670 nm. This dye was chosen because these wavelengths 
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correspond to regions of the spectrum with low endogenous optical signal [62]. This 
contrast agent allows fluorescent imaging of EGFR. Fluorescently labeled EGF has been 
used in vivo previously for imaging of mammary tumors in mice [71, 72]. 
An alternate way to target EGFR is to use an antibody to the receptor. A 
fluorescent EGFR antibody can be prepared by conjugating an Alexa Fluor 647 dye to the 
amine groups on the antibody. This contrast agent is purified using size exclusion 
chromatography to remove any free dye from the labeled antibody. Fluorescent anti-
EGFR has been used to detect the receptor in tissue using imaging or spectroscopy [61, 
73-76]. 
2.4.2 2-NBDG 
2-(N-(7 -nitrobenz-2-oxa-1 ,3-diazol-4-yl)amino )-2-deoxyglucose (2-NBDG) is a 
commercially available fluorescent glucose analog consisting of a glucose molecule 
attached to a fluorescent dye, shown in Figure 2-2 [77]. It is a small molecule with a 
molecular weight of 342.26 g/mol. 2-NBDG's fluorophore excites at 470 nm, and emits 
with a peak at 550 nm. The excitation emission matrix (EEM) for 2-NBDG is shown in 
Figure 2-3. This contrast agent was developed as a fluorescent indicator of glucose 
uptake activity in cells [77, 78]. The glucose component allows 2-NBDG to be 
transported through the GLUT transporters and be internalized by live cells, resulting in 
cytoplasmic fluorescence. This contrast agent has been used to visualize the level of 
cellular metabolism, a characteristic that is increased in the rapidly growing and dividing 
cells of dysplasia and cancer [79]. High metabolism and the associated increased 
cytoplasmic fluorescence from 2-NBDG can therefore identify cells experiencing the 
uncontrolled growth associated with neoplasia. 2-NBDG is an optical analog of 18F-
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FDG, which is routinely used in positron emission tomography (PET). While 2-NBDG is 
not yet approved for human use, 18F-FDG has been used as a contrast agent for PET for 
many years without significant deleterious side effects. 
Figure 2-2. Chemical structure of2-NBDG 
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Figure 2-3. Excitation emission matrix of 2-NBDG, intensity is normalized to a 
maximum value of 1 
2.4.3 Proflavine 
Like other acridine compounds, proflavine binds reversibility and non-covalently 
to nucleic acids by intercalating between adjacent base pairs [80]. Its chemical structure 
is shown in Figure 2-4. Although proflavine is not molecular-specific, its binding to 
DNA distinguishes nuclei from the cytoplasm of the cell. High-resolution fluorescent 
imaging of this agent in tissue can give information about inter-nuclear spacing and 
nuclear to cytoplasmic ratio, both important metrics used in the histological diagnosis of 
cancer. Proflavine has a broad excitation range with its peak at around 430 nm, and emits 
light with a peak around 515 nm. The excitation emission matrix for proflavine is shown 
in Figure 2-5. Proflavine has been used clinically as a topical antibacterial agent, and has 
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also been used topically in humans in an investigational in vivo study of gastrointestinal 
cancer [81, 82]. While acriflavine is not currently FDA approved, an investigational new 
drug (IND) application has been filed and accepted for a few specific in vivo protocols 
for head and neck and gastrointestinal cancer patients. 
Figure 2-4. Chemical structure of proflavine 
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Figure 2-5. Excitation emission matrix of proflavine, intensity ts normalized to a 
maximum value of 1 
When used in combination, the contrast agents described here can provide 
information about tissue architecture and about functional, molecular-specific alterations 
that occur due to neoplasia. 
2.5 Optical Systems 
2.5.1 Multi-spectral Digital Microscope 
The Multispectral Digital Microscope (MDM) is a wide-field fast-acquisition 
imaging device that is capable of capturing white light and fluorescent images. It 
consists of a commercially available dental surgical microscope, a mercury arc-lamp light 
source, excitation and emission filter wheels, two scientific-grade high-resolution color 
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CCD cameras, a computer, and custom adaptors needed to modify the microscope [83]. 
The field of view of the device depends on the magnification setting but can range 
between one and four centimeters. Figure 2-6 shows the optical diagram of this 
instrument. 
CCD 
Illumination filter wheel 0 
Collection I!E!'!e!l 
filter wheel 
Tissue 
Figure 2-6. Optical diagram of the Multispectral Digital Microscope 
The MDM has been used in clinical pilot studies to examine the endogenous 
contrast present in normal versus precancerous and cancerous tissue [83]. Cancer and 
precancer display a loss of autofluorescence in a broad portion of the spectrum due to 
alterations in the concentration of endogenous fluorophores in the tissue in response to 
neoplasia. Example images of abnormal tissue from the oral cavity demonstrating this 
loss of fluorescence in a few different wavelengths are shown in Figure 2-7. 
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Figure 2-7. Example MDM images of oral mucosa with mild to moderate dysplasia in the 
regions showing loss of autofluoresence 
While endogenous contrast exists, using the exogenous contrast agents proposed 
here could potentially improve the ability of the MDM to detect cancerous lesions. The 
molecular-specific agents provide information about the lesions that cannot be obtained 
through autofluorescence imaging alone, which may help to distinguish cancer from other 
confounding conditions such as leukoplakia, inflammation, and hyperkeratosis. Since the 
MDM is able to image fluorescence over a wide field of view, the oral cavity could be 
quickly surveyed to detect abnormal regions. 
2.5.2 High Resolution Microendoscope 
The high resolution microendoscope (HRME) is a fiber-optic fluorescence 
imaging system capable of sub-cellular resolution [84]. It consists of an LED light 
source, a flexible fiber-optic bundle, a lOx/0.25 NA microscope objective lens, and a 
CCD camera. The LED emits light centered at 455 nm (20 nm FWHM). Fluorescence 
emission from the sample is collected through the fiber optic bundle, transmitted through 
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a 475 run cut-off dichroic mirror, and imaged onto a CCD camera via a tube lens. The 
field of view depends on the size of the fiber bundle, but can range from 350 to 750 
microns. The resolution of the instrument is less than 4 microns. The optical design is 
shown in Figure 2-8. 
Figure 2-8. Optical design of the high resolution microendoscope (figure adapted from 
Rosbach et al., 2010 [85]) 
The HRME has been used with proflavine as a contrast agent to image nuclear 
size and spacing in ex vivo oral and esophagus tissue samples in clinical pilot studies 
[86]. Nuclear to cytoplasmic ratio can be assessed, which is an important metric in 
histopathologic diagnosis. The advantage of the HRME over traditional histopathology is 
that the tissue can be imaged in real time, allowing a faster diagnosis that does not require 
tissue removal. The small size of the fiber bundle also means that the HRME can be 
inserted through a needle and used for imaging sub-surface tissue. This aspect makes 
HRME imaging with proflavine contrast accessible to deeper tissues; this idea is 
extended to imaging lymph nodes from breast cancer patients in a study described in this 
thesis. An example HRME image of normal lymphatic tissue is shown in Figure 2-9. 
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Normal Node 
Figure 2-9. (A) HRME image taken from a malignant lymph node (B) HRME image 
taken from normal lymphoid tissue, photograph of nodes shown above was taken with the 
MDM with the site of HRME imaging indicated with a red circle 
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2.6 Conclusions 
Because of the high prevalence of confounders in the oral cavity and the lack of 
specificity of current detection aids, optical molecular imaging could serve as an 
important tool for examining biomarker expression levels in disease and confounding 
states to help identify features that correlate with the presence of disease. The 
availability of molecular-specific information from optical imaging may help improve the 
specificity of screening and elucidate the role biomarkers play in the disease process. 
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CHAPTER 3: OPTICAL MOLECULAR IMAGING OF EGFR EXPRESSION 
TO IMPROVE DETECTION OF ORAL NEOPLASIAt 
3.1 Abstract 
Background: The development of non-invasive molecular imaging approaches has 
the potential to improve management of cancer. Methods: In this study, we demonstrate 
the potential of non-invasive topical delivery of an epidermal growth factor-Alexa 647 
(EGF-Alexa 647) conjugate to image changes in epidermal growth factor receptor 
(EGFR) expression associated with oral neoplasia. We report a series of pre-clinical 
analyses to evaluate the optical contrast achieved following topical delivery of EGF-
Alexa 64 7 in a variety of model systems, including cells, three dimensional tissue 
cultures, and intact human tissue specimens using widefield and high-resolution 
fluorescence imaging. Data was collected from seventeen different oral cancer patients: 
eight pairs of normal and abnormal biopsies and nine resected tumors were examined. 
Results: The EGF-dye conjugate can be uniformly delivered throughout the oral 
epithelium with a penetration depth exceeding 500 microns and incubation time of less 
than 30 minutes. Following EGF-Alexa 647 incubation, the presence of oral neoplasia is 
associated with a 1.5-6.9 fold increase in fluorescence contrast as compared to grossly 
normal mucosa from the same patient with both widefield and high-resolution 
fluorescence imaging. Conclusions: Results illustrate the potential of EGF-targeted 
fluorescent agents for in vivo molecular imaging, a technique that may aid in the 
1 This chapter has been published previously in Nitin N, Rosbach KJ, El-Naggar A, Williams M, 
Gillenwater A, and Richards-Kortum RR (2009). Optical molecular imaging of epidermal growth factor 
receptor expression to improve detection of oral neoplasia. Neoplasia 11, 542-551. 
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diagnosis and characterization of oral neoplasia and allow real-time detection of tumor 
margins [87]. 
3.2 Introduction 
Non-invasive, molecular-specific imaging has the potential to improve 
management of oral neoplasia by allowing characterization of specific molecular 
alterations, facilitating the individualized selection of therapy, and enabling real-time 
evaluation of treatment response [88-94]. Genetic changes that occur during 
carcinogenesis lead to altered gene expression and protein levels as compared to normal 
cells. A number of promising molecular biomarkers of early oral neoplasia have been 
identified [95-99], including several specific mutations and molecular abnormalities that 
occur during the transition from normal mucosa to dysplasia to invasive carcinoma [100-
104]. These molecules can serve as biomarkers for early detection strategies and follow 
up of high-risk individuals. Although these data herald a breakthrough for deciphering 
the mechanisms of oral carcinogenesis, they were obtained through analytical techniques 
requiring tissue from invasive biopsies or surgical resections. Unfortunately, there are 
currently no techniques available to rapidly screen for these changes at the point-of-care. 
The clinical use of molecular imaging in cancer patients has focused primarily on 
positron emission tomography (PET). PET uses 18F-FDG (fluorodeoxyglucose) or 18F-
FLT (3'-Deoxy-3'-18F-fluorothymidine) as contrast agents to provide images with 
molecular information and is now routinely used for staging and assessment of treatment 
response in cancer patients [1 05-1 07]. While PET imaging has important clinical 
advantages, it has had a limited role in cancer screening and early detection due to its 
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limited spatial resolution and cost associated with cyclotron and radio-imaging facilities. 
An additional major drawback of PET is radiation exposure to the patient. 
Optical imaging of tissue autofluorescence has emerged as a strategy for detection 
and diagnosis of oral lesions [108, 109], and is favorable due to its ability to image tissue 
with high spatial (less than 1 micron lateral resolution) and temporal resolution (usually 
video rate) using low-cost, portable devices. However, performance of autofluorescence 
imaging systems does not always represent an improvement over common white light 
inspection [110]. Combined fluorescence diagnosis using both autofluorescence and 5-
aminolevulinic acid (5-ALA)-induced protoporphyrin IX (PPIX) fluorescence shows 
improved sensitivity and specificity over autofluorescence alone, but cannot be 
performed as quickly [110, 111]. Permeation of 5-ALA through mucosa is highly 
variable, especially in the presence of keratin, and as a result, keratinized oral lesions, 
especially those exhibiting hyperkeratosis, may be more difficult to diagnose [112]. 
An alternative approach is optical molecular imaging [6, 93, 113-115] which 
combines the advantages of molecular-specific imaging with the strengths of optical 
imaging. For clinical application, a successful optical molecular imaging strategy must 
solve several challenges: it must utilize a contrast agent which can be effectively and 
safely delivered to a target tissue in vivo, and it must yield images of tissue in real time 
with the desired spatial resolution and field of view, with a high signal to noise ratio. 
Optical imaging of fluorescent contrast agents has been used previously to discriminate 
cancer cells from normal cells, such as the chlorotoxin:Cy5.5 contrast agent [25]. While 
this agent binds to multiple types of cancer cells, it is not specific for a single target. 
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The epidermal growth factor receptor (EGFR) is an established biomarker for 
detection of oral neoplasia [116-119] and also has potential prognostic value [120]. 
Although EGFR is present in proliferating cells in normal tissue [121] there is marked 
over-expression during progression to dysplasia and cancer [122]. An estimated 50-98% 
of oral cancers overexpress EGFR [64, 65, 67, 68, 123]. EGFR expression was a strong 
prognostic indicator for overall and disease-free survival in patients with advanced head 
and neck squamous cell carcinoma enrolled in a radiotherapy study and was highly 
predictive for local-regional relapse but not distant metastases [66]. 
The goal of this study was to develop and evaluate the potential of a topically 
delivered optical contrast agent to image EGFR expression for use in the early detection 
of oral neoplasia. We report a series of pre-clinical analyses to assess the potential of 
topically delivered EGF-Alexa 647 for molecular imaging of oral neoplasia; we evaluate 
the resulting optical contrast achieved in cells, three dimensional tissue cultures, paired 
clinically normal and abnormal biopsies, and surgically resected oral tumors. High-
resolution fluorescence imaging was used in biopsy specimens to evaluate the ability of 
the contrast agent to be delivered throughout the epithelium, and also to quantitatively 
assess image contrast. Widefield fluorescence imaging was used to assess the spatial 
heterogeneity of EGFR expression in resected tumors and to quantify the increase in 
fluorescence intensity of abnormal tissue. High resolution and widefield imaging of 
contrast provide complementary information that may be useful for better classification 
of disease state, detection of disease margins, and understanding spatial heterogeneity of 
biomarker expression. Contrast values achieved in the tissue specimens were compared 
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to the results of histopathologic diagnosis and immunohistochemical (IHC) analysis of 
EGFR expression. 
3.3 Materials and Methods 
3.3.1 Preparation ofEGF-Alexa 647 
To prepare EGF-Alexa 647 conjugate, EGF peptide (Calbiochem, MA) was 
labeled with Alexa 647-carboxylic ester (Invitrogen, CA) and purified using size 
exclusion chromatography and dialysis. This two-step purification was used to 
completely remove free dye from the labeled peptide; purification was monitored by 
spectroscopy. Murine derived recombinant EGF peptide was used for the studies in cells, 
tissue phantoms and biopsies, and human derived recombinant EGF peptide was used for 
the resected oral lesions. Control experiments (including cells and tissue phantoms) were 
performed to ensure these data could be combined. 
3.3.2 Incubation and Imaging of Cells and Tissue Phantoms 
To demonstrate the specificity of EGF-Alexa 647 based contrast agent, we 
incubated two cell lines with the conjugate. 1483 cells (provided by Dr. Lotan, M. D. 
Anderson Cancer Center) were selected as a representative EGFR positive cell line, while 
MDA-MB-435 cells (ATCC, VA) were selected as a representative EGFR negative cell 
line. The cells were incubated with EGF-Alexa 647 (0.01 mg/ml) for 30 minutes at 37 
°C and imaged live using a Zeiss LSM 510 confocal microscope (excitation at 633 nm, 
and emission filter band pass 650-700 nm). To further demonstrate specificity of the 
contrast agent, 1483 cells were first blocked with 1% BSA for 30 minutes and then 
incubated for one hour on ice with equimolar amounts of both EGF-Alexa 647 and anti-
EGFR antibody (monoclonal antibody clone 108, Baylor College of Medicine) labeled 
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with Alexa 488 (Invitrogen, CA). Additionally, a competition assay was performed in 
which 1483 cells were incubated for one hour on ice with EGF-Alexa 647 and unlabeled 
EGF. Incubation on ice was conducted to limit intracellular uptake of EGF receptors. 
The unlabeled EGF was added in concentrations of Ox, O.lx, lx, and lOx the molar 
concentration ofEGF-Alexa 647. 1483 cells were also incubated with rhodamine-labeled 
3 kD dextran, a nonspecific fluorescent agent with a similar size as EGF peptide. 
Concentration and incubation conditions for cells with dextran were identical to cells 
with EGF-Alexa 647. Appropriate power and gain settings to image the rhodamine-
labeled dextran with the confocal microscope were determined by first imaging a well 
with dextran that had not yet been washed, and adjusting settings to detect a strong 
fluorescence signal from these wells. These settings were then used to image cells that 
were incubated with dextran and washed. 
To assess the potential ability to topically deliver EGF-Alexa 647, a three-
dimensional tissue culture system was used. Tissue phantoms were prepared by placing a 
suspension of approximately 10 million 1483 or 435 cells in a collagen matrix [124]. 
Phantoms were cultured for 24 hours in a cylindrical chamber (Transwell Chambers, 
Costar, MA) prior to subsequent incubation and imaging. The EGF-dye conjugate was 
topically delivered to only the top surface area of the tissue phantom (0.05 mg/ml). After 
30 minutes of incubation, tissue phantoms were washed in excess media to remove 
unbound contrast agent. Following incubation, tissue phantoms were sliced transversely 
using a Krumdieck tissue slicer (Alabama Research & Development) (200-300 microns 
thick) and imaged using a Zeiss LSM 510 confocal fluorescence microscope using the 
same settings used for cell imaging. 
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3.3.3 Topical delivery of EGF- Alexa 64 7 in Clinical Samples 
To demonstrate the potential of EGF-Alexa 647 to detect oral neoplasia, the 
conjugate was topically applied to fresh tissue samples obtained from oral cancer 
patients. Paired sets of clinically normal and abnormal oral biopsies (n=8) were used 
initially to ensure translation of results from cells and tissue phantoms into human tissue. 
Once we confirmed contrast agent binding in biopsies, freshly resected oral tumors (n=9) 
were also incubated with the agent and analyzed. Patients gave written informed consent 
to participate, and the study was reviewed and approved by the Institutional Review 
Boards at the University of Texas M.D. Anderson Cancer Center and Rice University. 
EGF-Alexa 647 (0.05 mg/ml cone. in IX phosphate buffered saline, pH 7.4) was 
topically applied to these tissue samples in the presence of I 0% dimethylsulfoxide 
(DMSO). DMSO was used as a permeation enhancer to improve delivery of the EGF-
Alexa 647 conjugate through the epithelium of these tissue samples [I25-I27]. Samples 
were incubated with EGF-Alexa 647 for 30 minutes, washed with IX phosphate buffered 
saline, and imaged using a widefield fluorescence imaging system with appropriate 
excitation and emission filters. Widefield imaging was used to survey the tissue because 
it has a large field of view ( -5 x 7 em for these instruments). The biopsies were imaged 
with the CRiMaestro™ (Woburn, MA), a planar multispectral widefield imaging device. 
The resected oral tumors were imaged with a multispectral digital microscope, consisting 
of a modified widefield dental microscope capable of imaging in reflectance and 
fluorescence modes [83]. Appropriate control experiments were performed to ensure that 
data from these devices could be combined. To compare the increase in fluorescence 
intensity of incubated tissue, both pre-incubation and post-incubation images were 
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acquired. The pre-incubation image provided a measure of autofluorescence background 
signal from tissue. Following widefield imaging, the biopsy samples were sliced 
transversely to a thickness of 200-300 microns and imaged in both reflectance (to locate 
epithelial and stromal regions of tissue slices) and fluorescence (to detect contrast agent) 
modes using a confocal microscope (Zeiss LSM 51 0). This high-resolution imaging was 
used to assess penetration depth of the EGF-dye conjugate. All tissue was returned to the 
Pathology Department of the University of Texas M. D. Anderson Cancer Center for 
hematoxylin and eosin (H&E) staining and IHC processing. IHC staining for EGFR was 
performed by the Research Histology Core Laboratory at M. D. Anderson following 
standard protocol with a standard EGFR antibody (clone 3107 mouse anti-human, 
Zymed). 
To further validate the specificity of EGF-Alexa 647 in oral tissues, a resected 
oral lesion was incubated with rhodamine-labeled 3-kDa dextran in 10% DMSO as a 
nonspecific fluorescent agent with a similar size as EGF peptide. The concentrations of 
fluorescently labeled dextran and incubation conditions were identical to the experiments 
performed with EGF-Alexa 647. 
3.3.4 Quantification of Imaging Data 
Widefield fluorescence images of the oral tissue samples obtained pre- and post-
incubation were quantitatively analyzed using Photoshop 7.0 to calculate the mean 
fluorescence intensity (MFI) across the tissue surface. A differential contrast value was 
calculated by finding the ratio of the increase in the MFI of neoplastic tissue after 
incubation relative to the increase in the MFI of normal tissue. For the biopsies, paired 
sets of abnormal and normal biopsies from the same patients were used together; for the 
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resected oral lesions, a head and neck surgical oncologist identified regions of clinically 
neoplastic and normal tissue from white light images of the lesions. The physician was 
blinded to the results of fluorescence imaging. Differential contrast was calculated for 
each clinical sample; results were compared to histology and IHC staining for EGFR. 
Portions of the normal epithelium in the resected tumors displayed characteristics 
of hyperkeratosis or hyperplasia. While these conditions are benign, they may affect the 
autofluorescence patterns and act as confounding factors in diagnostic strategies based on 
autofluorescence alone [53, 128]. Additionally, the thickened epithelium may result in 
entrapment of contrast agent, leading to artificially high differential contrast values. To 
investigate the specificity of the differential contrast approach with EGF-Alexa 64 7 and 
ensure that these conditions will not negatively affect our performance, differential 
contrast was calculated for regions of hyperkeratosis (n=4) and hyperplasia (n=4) as 
identified from histology slides by an expert head and neck pathologist. The epithelium 
in these regions was otherwise normal with no signs of dysplasia or cancer. Differential 
contrast was calculated for hyperkeratotic and hyperplastic regions relative to the same 
normal regions that were used previously; there was no overlap between these normal 
regions and regions of hyperkeratosis or hyperplasia. Differential contrast was also 
calculated for the tissue incubated with the rhodamine-labeled dextran as another control 
to investigate the specificity ofEGF-Alexa 647. 
High-resolution confocal fluorescence images of biopsy slices incubated with 
EGF-Alexa 647 were also analyzed to quantitatively calculate the MFI in the epithelial 
region of normal and dysplastic samples and regions containing tumor cells for tumor 
specimens. A ratiometric contrast value was calculated for each set of paired biopsies by 
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dividing the MFI of the clinically abnormal tissue by the MFI of the corresponding 
clinically normal sample. Results were compared to the histologic diagnosis of each 
biopsy set. 
3.4 Results 
Confocal fluorescence images of 1483 cells (EGFR positive) incubated with the 
EGF-Alexa 647 conjugate showed bright red fluorescence localized at the cell 
membrane; in contrast, images of MDA-MB-435 cells (EGFR negative) incubated with 
the agent did not show detectable signal under the imaging conditions used here (data not 
shown). 1483 cells incubated with both EGF-Alexa 647 and anti-EGFR antibody labeled 
with Alexa 488 showed co-localization of fluorescence signal at the cell membrane as 
shown in Figure 3-1 (upper). The competition assay with EGF-Alexa 647 and the 
unlabeled EGF showed a decrease in fluorescence signal with increasing concentrations 
of unlabeled EGF as shown in Figure 3-1 (lower). In addition, control experiments were 
also conducted using fluorescently labeled dextran. Images of cells incubated with 
rhodamine-labeled 3-kDa dextran did not show any binding to or retention of the 
nonspecific agent in cells. 
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EGF-Aiexa 647 EGFR Ab-Aiexa 488 
White Light Overlay 
Ox 0.1x 1x 10x 
Amount of unlabeled EGF added relative to EGF-Aiexa 647 
Figure 3-1. (Upper panel): EGFR positive 1483 cells co-incubated with EGF-Alexa 647 
(red) and an anti-EGFR antibody labeled with Alexa 488 (green) showing co-localization 
of fluorescence at the cell membrane. Scale bar is 20 microns. (Lower panel): 
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Competition assay of 1483 cells incubated with EGF-Alexa 647 and unlabeled EGF 
added at concentrations of OX, O.lX, IX and lOX the amount ofEGF-Alexa 647. Scale 
bar is 20 microns. 
To evaluate whether the EGF-Alexa 647 conjugate could be delivered topically, 
initial experiments were carried out in three dimensional tissue phantoms. Figure 3-2 
shows confocal fluorescence images of two transversely sliced tissue phantoms that were 
incubated with EGF-Alexa 647 before slicing. Fluorescence signal was observed 
throughout the phantom containing the EGFR positive 1483 cells, while no fluorescence 
signal was observed in the phantom containing the EGFR negative 435 cells. In some of 
the 1483 cells, internalization of the contrast agent was observed. These results 
demonstrate that selective targeting of EGFR receptors can be achieved in this model 
system with topical delivery and that excess contrast agent can be easily removed with a 
simple washing step. 
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EGFR Positive Tissue Phantom EGFR Negative Tissue Phantom 
Figure 3-2. High-resolution white light and fluorescence confocal images of three-
dimensional tissue culture phantoms incubated with the EGF-Alexa 647 conjugate. Scale 
bars are 1 00 microns. 
Next, EGF-Alexa 647 was topically delivered to fresh oral biopsies and resected 
lesions to demonstrate its ability to bind to human tissue. Figure 3-3A shows the white 
light widefield image of a representative tissue sample with the clinically neoplastic 
region outlined in yellow and a representative normal region outlined in blue. Figure 
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3-3B shows the widefield fluorescence image obtained after topical delivery of EGF-
Alexa 64 7 and removal of excess contrast agent. A pre-incubation image was obtained 
using the same instrument parameters in order to estimate levels of auto-fluorescence 
signal from the tissue sample; the background autofluorescence at these wavelengths was 
very low. Following incubation with the contrast agent, the fluorescence image shows 
greater fluorescence intensity in the neoplastic region as compared to the normal region. 
Fluorescence observed on the edges of this specimen occurs as an artifact of surgical 
cautery. Fluorescence intensity of the representative normal region and the neoplastic 
region is shown quantitatively in Figure 3-3C, which compares the mean fluorescence 
intensity pre- and post-incubation of each region. Figure 3-3D shows the results of IHC 
staining for EGFR in tissue taken from neoplastic and normal regions. The results show 
strong staining indicating a high level of EGFR throughout the neoplastic region as 
compared with only weak staining localized to the basal layer of the epithelium 
indicating a low level of EGFR in the normal region. The IHC analysis is in agreement 
with the results from widefield imaging on resected lesions. Pathological diagnosis for 
this representative case was invasive squamous cell carcinoma. 
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D 
Neoplastic Region Normal Region 
Figure 3-3. (A): Widefield white light image of resected oral lesion. The neoplastic 
region as selected by an expert clinician blinded to the results of fluorescence imaging is 
outlined in yellow; the representative normal region is outlined in blue. The histologic 
diagnosis was invasive cancer. Scale bar is 1 em. (B): Widefield fluorescence image of 
the same sample obtained after topical delivery of EGF-Alexa 64 7 and washing to 
remove excess dye. Scale bar is 1 em. (C): MFI of neoplastic and normal regions pre-
and post-incubation. All values are normalized to the intensity of the normal region pre-
labeling. (D): EGFR IHC stained sections from within the neoplastic and normal regions 
in the sample. Scale bars are 200 microns. 
The resected oral lesion labeled with 3-k.Da dextran as a nonspecific fluorescent 
agent is shown in Figure 3-4 in white light, after incubating with the rhodamine-labeled 
dextran, and after incubating with EGF-Alexa 647. Background fluorescence was 
subtracted out using pre-incubation images. No visible non-specific fluorescence is 
observed after incubation with dextran; after incubation with EGF-Alexa 647, the 
neoplastic region shows bright fluorescence. The orange pathology ink on the tissue 
results in the fluorescence seen on the tissue edges in Figure 3-4B. Pathological 
diagnosis for this sample was invasive carcinoma. 
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A) White Light 
B) Post- incubation with rhodamine-labeled 3 kD dextran 
C) Post- incubation with EGF-Alexa 647 
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Figure 3-4. (A): Widefield white light image of resected oral lesion with neoplastic 
region outlined in yellow. Scale bar is 1 em. (B): Fluorescence image of tissue after 
incubation with rhodamine-labeled 3kD dextran. The orange pathology ink is the cause 
of fluorescence observed near the edges of the tissue. (C): Fluorescence image of tissue 
after incubation with EGF-Alexa 647. 
A differential contrast value was calculated for each clinical sample to 
quantitatively compare fluorescence intensity increases in neoplastic and normal tissue. 
Figure 3-5 shows the differential contrast achieved for each specimen; the 
histopathologic diagnosis is also indicated. For samples with moderate to severe 
dysplasia (n=4), the differential contrast ranged from 1.6 to 3.9 with an average of 2.3. 
For samples with cancer (n=13), the differential contrast ranged from 2.0 to 6.9 with an 
average of3.8. 
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Figure 3-5. Differential contrast values calculated from widefield fluorescence images of 
fresh oral tissue incubated with EGF-Alexa 647 conjugate. Each data point represents a 
pair of tissue specimens from a single patient. The bars represent the average differential 
contrast and standard deviation for tissue with moderate to severe dysplasia (n=4) and 
tissue with cancer (n=l3). Differential contrast values for regions of hyperkeratosis and 
hyperplasia (n=8) are also indicated. 
To quantitatively examine the specificity of EGF-Alexa 647, regions of 
hyperkeratosis (n=4) and hyperplasia (n=4) were assessed for differential contrast value. 
The differential contrast obtained for these regions ranged from 0.8 to 1.2 with an 
average of 1.0. The contrast value of each region is also shown in Figure 3-5. To 
calculate a differential contrast value of the tissue incubated with dextran, images were 
taken at a long enough exposure time to detect a fluorescence signal. The fluorescence at 
this higher exposure, however, was fairly homogenous, as indicated by the calculated 
differential contrast of 1.04. Following incubation of the tissue with EGF-Alexa 647, the 
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differential contrast calculated (using the same regions of neoplastic and normal tissue) 
was 3.27. 
After widefield imaging of tissue samples, we obtained high-resolution confocal 
fluorescence images of transverse tissue slices prepared from biopsies incubated with 
EGF-Alexa 647. The aim of high-resolution imaging was to assess the tissue distribution 
of topically delivered EGF-Alexa 647 conjugate. Figure 3-6 shows images a 
representative pair of biopsies after incubation. Figure 3-6A shows images (fluorescence 
and IHC) of a clinically abnormal sample diagnosed as cancer, while Figure 3-6B shows 
images of a clinically and histologically normal sample from the same patient. The 
fluorescence images highlight significant differences in the contrast agent signal of the 
two samples; the cancer specimen showed strong uniform fluorescence around epithelial 
cell membranes. In contrast, the normal sample shows only weak fluorescence around 
epithelial cells near the basement membrane. The images in Figure 3-6A and Figure 
3-6B demonstrate permeation of contrast agents to depths in excess of 500 microns. No 
residual, non-specific fluorescence was observed in these images, suggesting that excess 
fluorescent contrast agent can be removed with simple washing. The results of high-
resolution optical imaging of EGFR expression in these clinical samples were validated 
using IHC analysis. The IHC images show strong expression of EGFR in the clinically 
abnormal biopsy but not in the corresponding normal sample. 
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Figure 3-6. (A): Confocal fluorescence image and IHC image of a clinically abnormal 
specimen incubated with topically applied EGF-Alexa 647 conjugate. The histologic 
diagnosis was invasive cancer. Scale bars are 100 microns. (B); Confocal fluorescence 
image and IHC image of a corresponding clinically and histologically normal specimen 
from the same patient incubated with topically applied EGF-Alexa 647 conjugate. The 
white line denotes the surface of the epithelium. Scale bars are 100 microns. (C): 
Ratiometric contrast ratio calculated from high-resolution fluorescence images of eight 
biopsy pairs incubated with EGF-Alexa 647 conjugate. Histologic diagnosis is indicated 
for each pair. 
A ratiometric contrast value was calculated for each set of paired biopsies (n=8 
pairs) to quantitatively compare MFI from the high-resolution fluorescence images of 
these samples. The ratiometric contrast for each biopsy set is shown in Figure 3-6C; the 
histopathology diagnosis is also indicated. The contrast is greater than 1.5 in all cases 
and ranges between 2-4 for most samples. 
3.5 Discussion 
In this study we evaluated the potential to image the expression of EGFR 
following topical delivery of fluorescently labeled EGF peptide for detection of oral 
neoplasia. We investigated the image contrast and topical delivery that could be achieved 
with this labeled peptide in both widefield and high-resolution imaging, translating 
results from cells and tissue phantoms to intact human tissue specimens. 
In widefield fluorescence images of fresh oral tissue diagnosed as moderate or 
severe dysplasia, we observed an average 2.3 fold increase in the fluorescence signal in 
neoplastic tissue as compared to normal tissue. For samples diagnosed as cancer, we 
observed an average 3.8 fold increase in fluorescence signal. The variability of 
differential contrast value between samples is expected due to patient-patient variability 
and also differences in levels ofEGFR expression in different sites within the oral cavity. 
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We also observed some overlap in differential contrast values between dysplasia and 
cancer. Despite these variations, differential contrast values can distinguish neoplasia 
from normal tissue; every neoplastic sample had a contrast value greater than 1.5. Our 
calculated contrast values are consistent with previous studies, which have shown that 
EGFR expression level increases approximately 2-5 fold with the development of 
neoplasia. The increase in EGF-Alexa 647 staining intensity is also consistent with the 
degree of staining observed in IHC analysis. 
Widefield imaging observations of differential contrast are paralleled by high-
resolution imaging observations of ratiometric contrast. Neoplastic oral biopsies showed 
a 2-4 fold higher fluorescence signal than paired normal biopsies. At the same time, 
normal specimens are associated with a small increase in fluorescence after topical 
application ofEGF-dye. We attribute this change to two possible factors. The first is the 
basal level of EGFR in normal oral epithelium, which can contribute to the increase in 
fluorescence signal by specific targeting. Second, we observed entrapment of some 
fluorescence contrast agent in the keratinized superficial layer of some specimens. This 
entrapment of EGF -dye was observed in the case of a few biopsy specimens, and could 
not be removed by simple washing steps. However, when differential contrast was 
calculated for regions of hyperkeratosis with underlying normal epithelium, and in 
regions of hyperplasia, the average differential contrast value was 1.0, which would be 
expected for a normal region. All regions of hyperkeratosis or hyperplasia had contrast 
values lower than any regions with moderate to severe dysplasia or cancer. In this study, 
neoplastic samples are therefore consistently associated with higher EGF staining than 
normal samples, even those with a thickened keratin layer or thickened epithelium. 
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Incubating tissue with the nonspecific fluorescent agent (rhodamine-labeled dextran) 
resulted in a differential contrast value of 1.04, which is significantly lower than any 
neoplastic sample. This result clearly demonstrates that EGF-Alexa 647 specifically 
targets neoplasia. 
We selected the EGF peptide to target the EGF receptor rather than an anti-EGFR 
antibody, which has been used in previous studies to label transverse sections of tissue 
slices. The EGF peptide (-6 kDa) is significantly smaller than antibodies (-150 kDa), 
and due to its small size it has increased tissue permeability and clearance of unbound 
contrast agent can be achieved with simple washing steps. Topical delivery of EGF 
peptide based contrast agents has the potential to overcome significant difficulties 
associated with targeting pre-invasive disease in oral tissue using IV delivery or sub-
cutaneous injections. In IV based delivery, the distribution of molecular contrast agents is 
controlled in large part by blood circulation. Since the epithelial layer is avascular, direct 
delivery of contrast agents to epithelial cells is limited using IV delivery. In addition, 
losses during circulation, especially for small peptides, can further reduce the effective 
concentration [129]. IV injected contrast agents typically require 24-48 hours of 
circulation time to achieve significant specific targeting of in tumor models. This 
significant delay can limit their use for screening. Further, many of the macromolecular 
contrast agents such as peptides are susceptible to degradation during such long 
incubation intervals [130]. 
One of the potential limitations in selecting naturally occurring growth factor 
ligands for molecular imaging applications is their ability to activate downstream cell 
signaling for proliferation. This observation has recently been reported using labeled 
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human EGF-peptide in implanted tumor cell lines [72]. To overcome this potential 
limitation, it is possible to select targeting peptides using library based screening 
approaches. Studies have shown the potential to select EGFR targeting peptides with 
reduced proliferative activity as compared to the natural EGF ligand [131, 132]. 
A potential limitation of widefield imaging alone is that it may be difficult to 
determine a precise margin of disease, especially if the tumor extends in the sub-mucosa, 
since the vast majority of photons collected with the current widefield imaging device 
come from the superficial three millimeters of tissue. However, widefield images are 
useful since they allow a quick survey of a large region of tissue and can be used to locate 
lesions and estimate disease margins. Even regions of moderate dysplasia that might not 
be obvious clinically displayed contrast agent binding that could be visualized with 
widefield fluorescence imaging. Once an approximate margin is determined from 
widefield images, high-resolution imaging can be used to refine this margin. Fiber optic 
confocal systems can be placed on or inserted beneath the tissue surface to allow 
assessment of contrast agent binding to cells along the perimeter, and therefore be used to 
determine a precise margin and detect sub-mucosal tumor extension. 
In summary, we have demonstrated non-invasive topical delivery of a molecular 
contrast agent to image changes in EGFR expression in oral neoplasia. Using a 
combination of widefield and high-resolution imaging we obtain quantitative contrast 
ratios to differentiate clinically neoplastic tissues from normal samples in both biopsies 
and resected oral lesions. The imaging results are in agreement with the pathological 
diagnosis as well as the IHC analysis. Results suggest that molecular imaging of EGFR is 
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a non-invasive approach that may have the potential to aid in molecular diagnosis and 
characterization of oral neoplasia in a clinical setting. 
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CHAPTER 4: OPTICAL MOLECULAR IMAGING OF MULTIPLE 
BIOMARKERS OF EPITHELIAL NEOPLASIA: EGFR EXPRESSION AND 
METABOLIC ACTIVITY IN ORAL MUCOSA 
4.1 Abstract 
Background: Biomarkers of cancer can indicate the presence of disease and also 
serve as therapeutic targets. An optical imaging approach using molecularly-targeted 
contrast agents can map out expression of multiple biomarkers simultaneously and with 
high spatial resolution. This tool examines biomarker expression level and heterogeneity, 
which have implications for improved disease detection and personalized medicine. 
Methods: To examine how biomarker expression correlates with the presence of disease 
in this proof-of-concept study, two clinically relevant biomarkers, epidermal growth 
factor receptor (EGFR) expression and metabolic activity, were assessed in nine samples 
of freshly resected oral mucosa using the topically applied optical imaging agents EGF-
Alexa 647 (to target EGFR) and 2-NBDG (to target metabolic activity). Quantitative 
features were calculated from the resulting fluorescence images and compared to 
histopathology maps of the tissue. Results: The EGF-Alexa 647 signal reflected EGFR 
expression level as indicated by immunohistochemistry. A classification algorithm 
developed using linear discriminant analysis resulted in an area under the curve of 0.83. 
Regions with a posterior probability from 0.80-1.00 contained >50% neoplasia 99% 
(84/85) of the time. Conclusions: This study demonstrates a proof-of-concept of how 
non-invasive optical imaging can be used as a tool to study expression level of multiple 
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biomarkers and their heterogeneity across a large mucosal surface area, and how 
biomarker characteristics correlate with the presence of neoplasia. Applications of this 
approach include predicting regions with the highest likelihood of disease, elucidating the 
role of biomarker heterogeneity in cancer biology, and identifying patients who will 
respond to targeted therapy. 
4.2 Introduction 
The molecular changes that accompany the progression of tissue throughout the 
dysplasia to carcinoma sequence can serve as diagnostic aids, therapeutic targets, 
surrogate end-points in clinical trials, or as an indication of recurrence [101, 133-135]. 
Many promising biomarkers of neoplasia have been identified and investigated. For 
example, in breast cancer patients, estrogen receptor positivity as indicated by 
immunohistochemistry (IHC) is not only associated with improved prognosis but also 
qualifies the patient for targeted hormonal therapy such as tamoxifen [136]. When it was 
recently discovered that 90% of gastrointestinal stromal tumors have an activating 
mutation in the KIT (CD117) receptor tyrosine kinase gene, a KIT inhibitor known as 
imatinib was developed which dramatically improved patient survival [137]. In ovarian 
cancer patients, serum level of CA125 is a well-established biomarker for monitoring 
treatment response or relapse [138]. While these examples highlight successful 
integration of biomarker information with disease management, the full picture of the 
role biomarkers play in cancer biology, the heterogeneity of their expression, and the 
implications biomarkers have on clinical management of patients is not always fully 
understood. We need a better understanding of the in vivo expression and the spatial and 
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temporal heterogeneity of these biomarkers and how they correlate with the presence of 
disease. 
To develop this understanding, we need the ability to simultaneously map out the 
distribution of multiple biomarkers across a large mucosal surface in vivo. An optical 
molecular imaging approach using targeted contrast agents is well suited for non-invasive 
imaging of eight or more biomarkers in distinct spectral bands with high spatial 
resolution, and may serve as an important tool in better understanding the role of 
biomarkers in the disease process [139]. The current gold standard of assessing protein 
expression, IHC, has some limitations, including the need to remove the tissue of interest 
for assessment and difficulty in reporting quantitative biomarker expression levels [140]. 
IHC is also unable to examine more than a single biomarker per slide, unless the proteins 
of interest lie in distinct compartments within the cell such as one marker in the nucleus 
and one in the cytoplasm. Information from multiple biomarkers frequently outperforms 
information from a single marker alone [136]. Breast cancer presents a good example of 
this in clinical practice, where estrogen receptor, progesterone receptor, and HER2/neu 
expression are all routinely assessed for prognosis and selection of therapy. High-
throughput methods to measure mRNA expression can simultaneously assess thousands 
of genetic indicators of disease, and though they are good screening tools to determine 
which biomarkers may be of interest in a particular cancer type, they generate more 
information than is clinically relevant and cannot provide information about spatial 
distribution. 
This study demonstrates a proof-of-concept of how non-invasive optical imaging 
with multiple topically applied targeted contrast agents could be used to study the 
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heterogeneity of biomarker expression and its correlation with the presence of neoplasia 
across a large mucosal surface area. The oral cavity was chosen as an organ site due to 
its accessibility to optical imaging, and the two clinically relevant biomarkers that were 
assessed in this study include the epidermal growth factor receptor (EGFR) and metabolic 
activity. Quantitative features of biomarker images are compared to the gold standard of 
histopathology. One example of how this approach may serve as an adjunctive tool to 
quantify and study biomarker expression and heterogeneity is discussed. 
EGFR is one of the most commonly studied biomarkers in cancers of the oral 
cavity because it is widely overexpressed in oral squamous cell carcinoma and dysplasia 
[ 141]. Though the reported percentage of patients with overexpression of EGFR varies 
between studies, a review from Lippman et al. indicates that 80-100% of patients with 
premalignant or malignant oral lesions have high EGFR expression [ 104]. EGFR 
expression level also increases with the progression of disease [69, 142-144]. A recent 
study from Taoudi Benchekroun et al. found that 71% of oral premalignant lesions 
display high EGFR expression levels, which correlated with a greater risk of developing 
oral cancer. Quantitative IHC studies reveal that the factor of overexpression of EGFR 
ranges from approximately 1.7- to 3-fold increase in dysplasia and cancer [69, 142, 145]. 
A similar level of overexpression was also observed in targeted molecular imaging 
studies [74, 87]. The prevalence of EGFR expression makes it a useful target for both 
detection and treatment; in fact, the EGFR inhibitor cetuximab is FDA approved for head 
and neck cancer therapy. 
Another clinical biomarker for oral cancer is increased metabolic activity. 
Metabolism is elevated in dysplasia and cancer due to rapid cell growth and division, so 
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glucose transporters (GLUTs) are often overexpressed or operate at a higher activity 
level. In a study by Kunkel et al., 100% ( 40/40) of oral cancers expressed GLUT -1 by 
IHC, and Mellanen et al. found that every tumor sample they examined expressed either 
GLUT-I or GLUT-3 mRNA [146, 147]. Ayala et al. found GLUT-I overexpression in 
50% of their oral cancer specimens [148], Tian et al. observed that 73.7% of samples had 
moderate to strong GLUT-I expression [149], and Ohba et al. discovered that 
overexpression of GLUT -1 in the invasion front is associated with the tumor depth and 
prognosis [150]. 
4.3 Materials and Methods 
4.3.1 Preparation of Fluorescent Imaging Agents 
To assess EGFR expression, the natural ligand of EGFR, the epidermal growth 
factor (EGF), was conjugated to a fluorescent dye. Purified human-derived recombinant 
EGF peptide (Calbiochem, San Diego, CA) was conjugated to Alexa Fluor 647-
carboxylic ester (Invitrogen, Carlsbad, CA). Excess free dye was removed by size 
exclusion chromatography followed by dialysis. The resulting EGF-Alexa 647 imaging 
agent was diluted to a final concentration of 25 jlg/mL in sterile IX phosphate buffered 
saline (PBS) with 10% dimethylsulfoxide (DMSO) as a permeation enhancer. 
Specificity studies in both cells and resected human tissue have been previously 
performed and published with EGF-Alexa 64 7, demonstrating the ability of this agent to 
specifically target EGFR in cell culture and in oral mucosa [87]. 
A fluorescently labeled glucose molecule was used to assess metabolic activity. 
2-(N-(7 -nitrobenz-2-oxa-1 ,3-diazol-4-yl)amino )-2-deoxyglucose (2-NBDG) is a 
commercially available optical glucose analog (Invitrogen, Carlsbad, CA). 2-NBDG was 
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diluted to a concentration of 0.16 mM in sterile IX PBS. Multiple published studies have 
used 2-NBDG as a metabolic activity indictor. Tumor cells in culture have been shown 
to take up approximately 5 times the amount of 2-NBDG compared to non-malignant 
cells, and competition assays with free glucose decreased the amount of 2-NBDG that 
was taken up [79]. A recent study by Sheth et al. demonstrated the comparability of 2-
NBDG to FOG-PET imaging in several preclinical examples, and Nitin et al. 
demonstrated the potential use of 2-NBDG for detecting neoplasia in clinical specimens, 
in which dysplasia and cancer displayed a 2- to 5-fold increase in fluorescence intensity 
compared to normal tissue [151, 152]. 
4.3.2 Application of Fluorescent Imaging Agents onto Clinical Samples 
To evaluate the ability of 2-NBDG and EGF-Alexa 647 to identify neoplasia in 
human oral tissue, freshly resected clinical specimens were obtained from patients 
undergoing surgery at M. D. Anderson Cancer Center. These patients gave written 
informed consent to participate in the study, which was approved by the Institutional 
Review Boards at both M.D. Anderson Cancer Center and Rice University. Neoplastic 
tissue was obtained immediately following surgical resection and taken to a lab for 
contrast agent application and subsequent imaging. 
To assess autofluorescence before the application of any fluorescent contrast 
agents, the tissue was imaged with a multispectral digital microscope (MOM), a 
widefield imaging system that has been described in detail previously [83]. Briefly, the 
MOM is a dental microscope that has been modified with fluorescence excitation and 
emission filters and a mercury-argon light source; it is capable of imaging in both 
reflectance and fluorescence modes. It has a large field of view ( -5 x 7 em) and can 
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achieve a lateral spatial resolution up to 0.016 mm. Pre-incubation images of the tissue 
were taken using standard white light setting and the filter configurations for 2-NBDG 
(ex. 475, em. 550) and EGF-Alexa 647 (ex. 650, em. 670) to allow later subtraction of 
tissue autofluorescence from post-incubation images. 
After autofluorescence imaging, 2-NBDG solution was topically applied to the 
epithelial surface of the resected oral tissue and placed in an incubator at 37 oc for 20 
minutes. Following incubation with 2-NBDG, the tissue was briefly rinsed with sterile 
IX PBS to remove any excess unbound fluorescent contrast agent. The tissue was again 
imaged with the MOM using the filter configurations for 2-NBDG and EGF-Alexa 647. 
Next, EGF-Alexa 647 in 10% DMSO was topically applied to the epithelial surface of the 
tissue and incubated for 20 minutes at 3 7 °C. The tissue was briefly rinsed with sterile 
lX PBS and imaged using appropriate filter settings on the MOM. 
Once imaging was complete, the entire tissue was returned to the Pathology 
Department of M. D. Anderson Cancer Center. The tissue was processed following 
standard procedures: the tissue was thinly sliced anterior to posterior and placed into 
cassettes for H&E staining. Locations of pathology cuts were documented and the 
portion of the tissue that was placed into each cassette was recorded to allow for future 
correlation to pathology. Neither 2-NBDG nor EGF-Alexa 647 affects histopathology 
processing or staining. 
4.3.3 Creation of Histopathology Maps 
To compare the results of widefield imaging with the gold standard of 
histopathology, a two-dimensional color-coded pathology map was synthesized for each 
clinical specimen. To create this map, all the H&E slides for each specimen were 
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reviewed with an expert Head and Neck Pathologist blinded to the optical images (MW). 
The diagnosis across the entire epithelium was recorded for each slide. This expert 
diagnosis from the slide was assumed to represent the diagnosis for the entire thickness of 
the thin piece of tissue that was placed in the corresponding cassette. The diagnoses of 
normal epithelium; mild, moderate, and severe dysplasia; and cancer were all assigned a 
unique color code. Based on detailed notes of where the tissue was sliced and the 
diagnosis across the epithelium for each piece of tissue, the color-coded histopathology 
map was created as an overlay on top of the white light image of the clinical specimen. 
The resulting two-dimensional histopathology map was used as a gold standard to 
compare with the widefield fluorescence images. Creation of a histopathology map is not 
standard practice in pathology, and in order to create an accurate map, the tissue had to 
have a fairly flat surface, slicing had to be strictly monitored and documented, and a 
detailed pathology reading across the entire surface had to be obtained and recorded. All 
the tissue samples used in this study met these criteria. 
4.3.4 Immunohistochemistry to confirm EGFR expression 
The Research Histology Core Laboratory at M. D. Anderson Cancer Center 
performed immunohistochemical staining for EGFR on multiple specimens in order to 
confirm that imaging results correlated with the gold standard indicator for the presence 
of EGFR. A standard staining protocol was followed using the Research Histology Core 
Laboratory's standard antibody for EGFR (clone 31G7 mouse antihuman; Zymed, South 
San Francisco, CA). An expert Head and Neck Pathologist reviewed these slides to grade 
the intensity of staining across the entire epithelial surface. The scale used for 
assessment of intensity of EGFR immunostaining was from zero to three. Score 0 
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indicated no staining or non-specific staining, score 1 was used for weak staining of 
> 10% of cells, score 2 indicated moderate staining of > 10% of cells, and score 3 
indicated strong and complete staining of> 10% of cells [ 153]. 
Immunohistochemistry for GLUT expression was not compared with fluorescence 
imaging results with 2-NBOG because while IHC can reveal GLUT expression level, it 
cannot assess GLUT activity level. Previous studies have not found a significant 
correlation between overexpression of glucose transporters and standardized uptake 
values of FOG in FOG-PET imaging, a widely accepted clinical method of analyzing 
metabolic activity [149, 154]. 
4.3.5 Quantitative Analysis of Fluorescence Images 
Post-incubation fluorescence images of both 2-NBOG and EGF-Alexa 647 were 
analyzed using Matlab R2010b software (The MathWorks, Natick, MA) to identify 
trends that might distinguish between diagnostic categories. All images pre- and post-
incubation were aligned using a built-in image registration algorithm. The fluorescence 
images were converted to grayscale and background autofluorescence was subtracted. 
For each clinical sample, multiple square regions 50 x 50 pixels in size were selected, 
using the histopathology map as a guide to ensure that each region selected contained a 
uniform diagnosis and that regions did not overlap. Statistical features were calculated 
and compared to feature values from regions of normal tissue to determine if these 
characteristics were altered in neoplastic tissue. These features included mean intensity, 
standard deviation, skewness, kurtosis, and the coefficient of variation within each 
region. Additionally, a Matlab edge detection algorithm using the Canny method was 
applied to the bulk fluorescence image in order to detect where sharp gradients in 
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intensity occurred because this may also serve as a measure of heterogeneity of 
biomarker expression. The length of this edge line divided by the number of pixels in the 
region was calculated for all selected regions and considered a candidate feature in the 
classification algorithm. 
4.3.6 Development of a Classification Algorithm 
To discriminate normal from neoplastic regions of interest based on these 
quantitative feature values, a classification algorithm was developed using linear 
discriminant analysis. The algorithm used all of the 50 x 50 pixel regions for both 
training and testing. Features were selected sequentially to identify which were most 
useful in distinguishing neoplastic tissue from normal tissue. Only three features were 
chosen in order to avoid over-training of the algorithm. Sensitivity, specificity, and area 
under the receiver operator characteristic curve (AUC) were calculated. 
4.3.7 Application of Classification Algorithm to a New Data Set to Predict 
Regions with the Highest Likelihood of Disease 
We examined the ability of this algorithm to identify regions of interest with the 
highest likelihood of disease, information that could be useful for early detection and 
diagnosis, planning surgical resection, monitoring treatment response, or screening for 
recurrence. A 50 x 50 pixel grid was used to divide the original fluorescence images from 
all the patients into new regions of interest. The classification algorithm described 
previously was applied to these regions in order to generate posterior probabilities (a 
value between zero and one) for all the new regions. The practical application of this 
strategy would be to help a clinician objectively identify areas with the highest likelihood 
of disease, including determination of the best place to take a biopsy in order to confirm 
63 
the presence of neoplasia. The regions with posterior probabilities from 0.80-1.00 were 
identified and compared to histopathology map information at that site. Regions with 
posterior probabilities from 0.60-0.79 were also identified as regions likely to be 
neoplastic, and this prediction was compared to the histopathology gold standard to 
assess performance of the algorithm. Only regions that contained epithelium throughout 
the entire 50 x 50 pixel region were evaluated, meaning that regions overlapping the edge 
of the tissue were not considered. 
The same analysis was applied to the remaining specimens. Each region 
identified as having a high posterior probability was compared to the gold standard 
histopathology map to determine if more than 50% of the identified region contained 
neoplasia. 
4.4 Results 
Nine distinct clinical specimens from different patients were incubated with both 
2-NBDG and EGF-Alexa 647 and imaged as described. Histopathology maps were 
created for these nine specimens to allow analysis of the fluorescence signal from 
different diagnostic categories. Figure 4-1 shows images from two representative clinical 
specimens: one with mild to moderate dysplasia and one with cancer. The figure 
includes a white light photograph of the tissue, post-incubation fluorescence images after 
application of2-NBDG and EGF-Alexa 647, and the corresponding histopathology map. 
Qualitative comparison of the fluorescence images and the gold standard histopathology 
maps of both samples demonstrates that for both imaging agents, there is greater 
fluorescence intensity in areas of neoplasia, including areas of invasive carcinoma as well 
as in areas of mild to moderate dysplasia. 
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Figure 4-1. Two representative specimens. The tissue is shown first in white light, next 
in fluorescence after incubation with EGF-Alexa 647 to show EGFR expression, then in 
fluorescence after incubation with 2-NBDG to show metabolic activity, and fmally with 
the corresponding histopathology map. Qualitative observation shows that areas of high 
fluorescence correspond to areas of neoplasia. Scale bars are 1 em. 
4.4.1 Immunohistochemistry to confirm EGFR expression 
IHC staining for EGFR was performed on multiple slides from this set of 
specimens in order to confirm previously published findings. IHC staining intensity 
correlates well with fluorescence intensity, confirming specificity of EGF-Alexa 647 
(images not shown). 
4.4.2 Quantitative Analysis of Fluorescence Images 
Figure 4-2 shows a representative sample with the outlines of the selected 50 x 50 
pixel regions of interest. This example contains 4 normal regions, 3 regions of mild 
dysplasia, 9 regions of moderate dysplasia, and 3 regions of severe dysplasia. The 
65 
regions are oriented parallel to the pathology slices in order to maximize the number of 
regions that could be selected per sample. Table 4-1 details the number of regions that 
were selected per sample by diagnostic category. Overall, 286 total regions were selected 
and were categorized as follows: 87 normal regions, 57 regions with mild dysplasia, 26 
regions with moderate dysplasia, 20 regions containing severe dysplasia, and 95 regions 
with cancer. 
Figure 4-2. Representative example of how 50 x 50 pixel regions were selected. This 
sample contains 4 normal regions, 3 regions of mild dysplasia, 9 regions of moderate 
dysplasia, and 3 regions of severe dysplasia. Quantitative features were calculated from 
each region of interest. Scale bar is 1 em. 
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Table 4-1. Number of analyzed regions by patient and diagnosis 
Specimen Normal Mild Moderate Severe Cancer Total 
# D~sElasia D~sElasia DysElasia 
1 4 3 9 3 0 19 
2 18v 1 1 0 12 32 
3 14 3 0 15 4 36 
4 12 33 8 0 0 53 
5 9 6 3 2 17 37 
6 9 3 3 0 23 38 
7 3 2 1 0 2 8 
8 6 1 1 0 23 31 
9 12 5 0 0 15 32 
Total 87 57 26 20 96 286 
4.4.3 Development of a Classification Algorithm 
For each region, statistical features including average intensity, standard 
deviation, skewness, kurtosis, maximum value and coefficient of variation were 
calculated from both kinds of post-incubation fluorescence images. Additionally, the 
length of the edge line detected using the Matlab edge function was calculated for each 
region using both fluorescence images. These statistical features were used to train and 
test a classification algorithm on the full set of 286 regions. Table 4-2 indicates the 
classification performance of the top six highest performing single features, ranked by 
AUC. Of the top six features, four features are calculated from the EGF-Alexa 647 
signal and two features are calculated from the 2-NBDG signal. Normalized mean 
intensity of the EGF-Alexa 647 signal was the highest performing single feature with an 
AUC of0.80. Table 4-2 also indicates the AUC ofthe three-feature algorithm developed 
from a combination of quantitative features as described below. 
Table 4-2. Performance of single feature in classification algorithm 
Feature 
EGF Mean Intensity 
EGF Entropy 
EGF Standard Deviation 
NBDG Mean Intensity 
EGF Maximum Value 
NBDG Maximum Value 
NBDG Edge Detection (5x threshold) 
NBDG Edge Detection (2x threshold) 
EGF Edge Detection (original threshold) 
NBDG Standard Deviation 
AUC of Single Feature 
0.80 
0.76 
0.73 
0.70 
0.70 
0.68 
0.68 
0.67 
0.66 
0.65 
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Figure 4-3 shows scatter plots of four selected features of interest, with the y-axis 
indicating feature value and the x-axis sorted by pathologic diagnosis. Figure 4-3A 
shows normalized mean intensity of the 2-NBDG signal, Figure 4-3B shows normalized 
intensity of the EGF-Alexa 647 signal, Figure 4-3C shows the coefficient of variation 
from the 2-NBDG signal, and Figure 4-3D shows the length of the detected edge divided 
by number of pixels based on the 2-NBDG signal. Ultimately, three features were 
selected for use in the classification algorithm: (1) normalized mean intensity of the EGF-
Alexa 647 signal, (2) coefficient of variation from the 2-NBDG signal, and (3) length of 
the detected edge based on 2-NBDG. The features were selected sequentially in that 
order for improving performance of the algorithm; normalized mean intensity of the 
EGF-Alexa 647 signal was the single best feature, and each of the subsequent features 
improved algorithm performance. Addition of a fourth feature to the algorithm did not 
significantly improve performance. 
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Figure 4-3. Scatter plots showing the distribution of feature values within the set of 286 
regions, each point represents a single region. Regions are grouped by pathologic 
diagnosis with green indicating normal epithelium, blue indicating mild dysplasia, pink 
indicating moderate dysplasia, red indicating severe dysplasia, and black indicating 
cancer. Horizontal black lines indicate the mean feature value and vertical black lines 
indicate the standard deviation for each pathologic category. The scatter plots show the 
following features: (A) Mean intensity of the 2-NBDG signal, (B) Mean intensity of the 
EGF-Alexa 647 signal, (C) Coefficient of variation in the 2-NBDG signal, and (D) 
Length of edges detected by the Canny method in the 2-NBDG signal (helps with 
classification of severe dysplasia). 
Figure 4-4A shows the resulting scatter plot of posterior probabilities grouped by 
histopathological diagnosis. The horizontal line at 0.41 indicates the cut-off point that 
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gives the best sensitivity and specificity of the algorithm. Any posterior probability 
above this value would be considered neoplastic by the classification algorithm, and any 
posterior probability below this value would be considered normal. This cut-off gives a 
sensitivity of 73% and a specificity of 77%. Figure 4-4B shows the receiver operator 
characteristic curve of the algorithm. The area under the curve (AUC) is 0.83, and the 
cut-off point yielding the highest sensitivity and specificity is marked with a blue circle. 
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Figure 4-4. (A) Scatter plot of posterior probability by diagnosis using the algorithm. The 
horizontal line indicates the optimum cut-off at 0.41. (B) Receiver operator characteristic 
curve using a three feature classification algorithm. The operating point at the optimum 
cut-off is shown with a blue circle and results in a sensitivity of 73%, a specificity of 
77%, and an area under the curve of0.83. 
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Figure 4-5A displays the 50 x 50 pixel grid that was used to divide the image 
from a representative samples into new regions. While the originally evaluated regions 
as shown in Figure 4-2 were selected to contain only one diagnostic category and were 
oriented parallel to the pathology slices, the new evaluation grid is oriented parallel to the 
edges of the image and each region may contain multiple diagnostic categories. Figure 4-
5B indicates the regions that were identified as having the highest posterior probability. 
Black stars indicate a posterior probability between 0.80-1.00 and gray stars indicate a 
posterior probability between 0.60-0.79. In this example, two adjacent regions have the 
highest level of posterior probability. According to the histopathology map, one of these 
regions contains mostly severe dysplasia, and the other contains mostly moderate 
dysplasia. Two regions with the second highest level of posterior probability were also 
identified, and these are also adjacent to one of the highest-level regions. Of these two 
regions, marked with a gray star, one contains mostly severe dysplasia and the other 
contains moderate dysplasia throughout. No part of any of these identified regions in this 
specimen contains normal epithelium. 
72 
··~ 
Posterior Probability Key: * 0.80-1.00 0.60-0.79 
Figure 4-5. (A) Superimposed grid to divide each specimen into a new set of regions. 
Using the previously developed classification algorithm, posterior probabilities were 
calculated for each of these new regions of interest. (B) Based on two levels of posterior 
probability, regions identified as most likely to contain neoplasia were marked with black 
(posterior probability: 0.80-1.00) or gray (posterior probability: 0.60-0.79) stars. Scale 
bars are 1 em. 
Table 4-3 shows the results of how many 50 x 50 pixel regions were identified 
based on each posterior probability threshold, and how many of these regions contained 
mostly neoplasia. Out of the nine specimens, seven specimens contained at least one 
region that had a posterior probability between 0.80-1.00, for a total of 85 regions. Of 
these identified regions, 99% (84/85) contained >50% neoplasia. The remaining two 
specimens that did not have any regions identified within the highest-level category (#3 
and #7) had multiple regions with posterior probabilities between 0.60-0.79. Among the 
9 specimens, a total of 85 different regions were identified as having a posterior 
probability from 0.60-0.79. Of these regions, 95% (81/85) contained >50% neoplasia. 
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Table 4-3. Use of posterior probability to identify regions with the highest likelihood of 
disease 
Regions with Posterior Regions with Posterior 
Probability of 0.80-1.00 Probability of 0.60-0.79 
Specimen Percent of regions containing >50% Percent of regions containing >50% 
# neoplasia neoplasia 
1 100% 100% (2/2) (2/2) 
2 93% 80% (13/14) (4/5) 
3 N/A 50% (1/2) 
4 100% 100% (1/1) (15/15) 
5 100% 80% (25/25) (8/10) 
6 100% 100% (31/31) (8/8) 
7 N/A 100% (3/3) 
8 100% 100% (11/11) (24/24) 
9 100% 
100% 
(1/1) (16/16) 
Total 99% 95% (84/85) (81/85) 
Figure 4-6 shows for all the clinical samples the regions determined to have the 
highest posterior probability overlaid onto the corresponding histopathology maps. The 
black stars indicate the regions with posterior probability from 0.80-1.00, and the gray 
stars indicate the regions with posterior probability from 0.60-0.79. A few of the regions 
identified do not have corresponding gold standard histopathology information for the 
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entire area and so were not included in the analysis shown in Table 4-3. Use of posterior 
probability to identify regions with the highest likelihood of disease, but are shown in 
Figure 4-6. 
Posterior Probability Key: * 0.80-1.00 0.60-0.79 
Figure 4-6. Based on two levels of posterior probability, regions identified as most likely 
to contain neoplasia were marked with black (posterior probability: 0.80-1.00) or gray 
(posterior probability: 0.60-0.79) stars. All clinical specimens examined are shown in 
this figure. Regions predicted to contain neoplasia have excellent agreement with the 
gold standard of histopathology. Scale bars are 1 em. 
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This strategy has excellent agreement with histopathology, and while it does not 
identify all abnormal tissue, it identifies areas with the highest likelihood of disease in all 
samples. 
4.5 Discussion 
The optical imaging approach described in this study uses molecularly-targeted 
contrast agents to simultaneously assess two clinically relevant biomarkers in oral cancer: 
EGFR expression and metabolic activity. The benefit of this approach is that expression 
levels of multiple biomarkers can be assessed quantitatively over a large field of view and 
with high spatial resolution; this type of information cannot be obtained through the 
current practice of IHC or PET imaging. These targeted imaging agents can be topically 
applied to the epithelial surface, decreasing the dose required in comparison with 
intravenous injection and reducing consequent systemic toxicity concerns. This approach 
could be extended to include other biomarkers, if spectrally distinct imaging agents that 
specifically target the biomarker can be developed. 
The classification algorithm described in this study identified regions with the 
highest likelihood of disease, areas that contained neoplasia 99% of the time. This 
objective assessment of accurately predicting the presence of disease has many clinical 
applications, including initial detection and diagnosis, selection of an appropriate biopsy 
site, monitoring treatment response, and monitoring patients for recurrence. This 
application is consistent with research recommended in 2010 in the Journal of the 
American Dental Association, which called for research projects to "identify factors that 
would increase clinicians' confidence and competence in identification and management 
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of potentially malignant lesions or early-stage malignancies, including the provision of 
surgical biopsies" [155]. 
Another potential use of a targeted optical imaging strategy could be in 
understanding the role of heterogeneity of biomarker expression in selection of therapy 
and predicting treatment response. EGFR expression is already a target in the FDA-
approved monoclonal antibody therapy cetuximab, which is often used to treat recurrence 
of oral cancer. Other EGFR inhibitors (gefitinib, erlotinib, panatumumab, and lapatinib) 
have been approved for cancer treatment in other organ sites and are currently in clinical 
trials for head and neck cancer indications [156]. While in vitro data suggest a link 
between EGFR expression level and cytotoxicity ofEGFR-targeted therapy, no definitive 
clinical correlation has yet been found [157-159]. As seen in the fluorescence images 
and IHC data shown here, EGFR expression is heterogeneous throughout a lesion. The 
ability to assess biomarker expression in vivo over a large sample using optical molecular 
imaging may elucidate the causes of this discrepancy and aid in the selection of patients 
who could benefit from EGFR-targeted therapy. For patients who respond, the benefits 
of EGFR-targeted therapy include the prevention of nodal metastases by blocking EGFR 
and potentially improved survival when combined with standard chemotherapy [160, 
161]. As new EGFR-targeted therapies (such as nimotuzumab, zalutulumab, 
bevacizumab, and vandetanib) are developed and tested clinically for head and neck 
cancer indications, predicting which patients may benefit from a particular therapy will 
also aid in FDA approval [162, 163]. 
EGFR expression also has applications in other clinical settings. EGFR may help 
distinguish between leukoplakia with or without dysplasia since oral leukoplakia with 
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underlying dysplasia has increased expression of EGFR, which may be useful as an early 
marker of malignancy [143]. Additionally, EGFR mRNA levels were shown to be lower 
in non-malignant leukoplakias compared to contra-lateral normal appearing mucosa from 
the same patient, though both patient sites had significantly higher EGFR expression than 
healthy volunteers had [164]. This result and the idea of field cancerization help explain 
why it is important to normalize each patient's information to a normal site from the 
same patient. For optical imaging with topically applied contrast agents in vivo, a contra-
lateral normal site could easily be assessed. Another clinical application of EGFR 
expression is in the identification of patients who would benefit from hyperfractionated 
accelerated radiotherapy [165, 166]. In pretreatment biopsies assessed for EGFR, 
patients with high EGFR expression had improved survival with hyperfractionated 
accelerated radiotherapy compared to a standard radiotherapy schedule. Identifying 
EGFR expression across the entire surface of the lesion may improve identification of 
patients who could benefit from this type of treatment. Finally, quantification of EGFR 
expression is difficult with current IHC methods, which may be one reason for 
conflicting findings in studies examining the prognostic value of EGFR in head and neck 
cancer [140]. Quantitative evaluation of optical molecular imaging of EGFR may help 
standardize measurement of EGFR expression level. 
Metabolic activity as indicated by FDG-PET is currently used extensively in head 
and neck cancer for tumor staging, monitoring treatment response, and detecting residual 
or recurrent disease [167, 168]. FDG-PET has a high sensitivity and moderate specificity 
for detecting recurrent disease at the primary tumor site, but due to its inherently low 
spatial resolution, it is unable to detect lesions smaller than approximately 1 em in size 
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[168]. FDG-PET is significantly better than clinical assessment and conventional 
imaging to monitor treatment response and has also been used as a marker of erlotinib 
response [169, 170]. Monitoring metabolic activity with FDG-PET can also identify 
residual disease and detect recurrence [ 168, 169, 171-173]. Although monitoring 
metabolic activity optically with 2-NBDG cannot accomplish any of the deep tissue 
applications of FDG-PET such as imaging of nodal metastases, it can be used to assess 
metabolic activity in the epithelium as shown in this study, a strategy which may be 
useful to detect residual or recurrent disease at the primary tumor site. The advantage of 
using 2-NBDG over FDG-PET is that optical imaging provides superior spatial and 
temporal resolution, does not expose the patient to ionizing radiation, and is far less 
expensive than PET imaging equipment and maintenance of cyclotron facilities. 
Optical molecular imaging as applied in this study has some limitations, however. 
Though topical application of imaging agents may reduce dose and toxicity concerns, the 
agents are delivered only in the epithelium, preventing detection of submucosal disease. 
Inflammation in the oral cavity is a common confounder for detection aids, and 
inflammatory cells may also take up 2-NBDG, resulting in potential false positives from 
high metabolic activity of lymphocytes present in oral tissue due to benign conditions. 
Additionally, not all patients will have overexpression of EGFR, so that low fluorescence 
signal after application ofEGF-Alexa 647 may not rule out the possibility of the presence 
of neoplasia. However, being able to obtain information from both agents in combination 
may help avoid the pitfalls of each agent alone. Another concern may arise from the idea 
of applying the epidermal growth factor, a mitogen, to a potentially neoplastic area. 
However, studies have demonstrated that pre-treatment of oral cancer lesions with EGF 
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actually improves the cytotoxicity of cisplatin, the most commonly used chemotherapy 
for head and neck cancer [174, 175]. 
Biomarkers have been studied for their potential use in detecting neoplasia, 
staging, selecting and monitoring therapy, detection of recurrence, and prognostic value, 
but the full picture of biomarker expression across an entire lesion is necessary to make 
accurate conclusions about the roles these biomarkers play in the disease process. 
Optical molecular imaging as demonstrated in this study of EGFR expression and 
metabolic activity in oral mucosa can reveal biomarker heterogeneity across a lesion and 
may serve as a research tool to understand cancer biology, develop new targeted 
therapies, or aid in the clinical management of cancer patients. With the proper imaging 
agents, this approach could be extended to monitor additional biomarkers in other types 
of epithelial neoplasia as well, and may eventually result in improved patient survival by 
allowing clinical care to be tailored to each patient's biomarker expression profile. 
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CHAPTER 5: HIGH-RESOLUTION FIBER OPTIC MICROSCOPY WITH 
FLUORESCENT CONTRAST ENHANCEMENT FOR THE 
IDENTIFICATION OF AXILLARY LYMPH NODE METASTASES IN 
BREAST CANCER: A PILOT STUDY2 
5.1 Abstract 
This prospective pilot study evaluates the potential of high-resolution fiber optic 
microscopy (HRFM) to identify lymph node metastases in breast cancer patients. 43 
lymph nodes were collected from 14 consenting breast cancer patients. Proflavine dye 
was topically applied to lymph nodes ex vivo to allow visualization of nuclei. 242 images 
were collected at 105 sites with confirmed histopathologic diagnosis. Quantitative 
statistical features were calculated from images, assessed with one-way ANOV A, and 
were used to develop a classification algorithm with the goal of objectively 
discriminating between normal and metastatic tissue. A classification algorithm using 
mean image intensity and skewness achieved sensitivity of79% (27/34) and specificity of 
77% (55/71). This study demonstrates the technical feasibility and diagnostic potential of 
HRFM with fluorescent contrast in the ex vivo evaluation of lymph nodes from breast 
cancer patients [85]. 
2 This chapter has been published previously in Rosbach KJ, Shin D, Muldoon TJ, Quraishi MA, Middleton 
LP, Hunt KK, Meric-Bernstam F, Yu TK, Richards-Kortum RR, and Yang W (2010). High-resolution fiber 
optic microscopy with fluorescent contrast enhancement for the identification of axillary lymph node 
metastases in breast cancer: a pilot study. Biomedical optics express 1, 911-922. 
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5.2 Introduction 
Breast cancer is the most common malignancy affecting women in North America 
and Europe, with approximately 200,000 new cases treated each year in the United States 
alone [176]. Treatment that involves surgical resection of the primary tumor often 
includes removal of axillary lymph nodes. The presence of axillary lymph node 
metastases is the most important prognostic factor for the patient, and determines 
appropriate adjuvant therapy after surgery [177]. However, axillary dissection is 
associated with significant short-term and long-term complications including 
lymphedema and upper extremity dysfunction in up to 50% of patients [178-180]. 
Identification and subsequent removal and assessment of the sentinel lymph node (SLN) 
has emerged as an alternative to full axillary dissection. This procedure has fewer 
complications than axillary dissection, however, there is potential for false negative 
events in 10-15% of patients [181-186]. This could result in understaging, which impacts 
adjuvant therapy recommendations, and the potential for regional recurrence in the axilla. 
An additional challenge for clinicians is the fact that touch imprint cytological analysis at 
the time of SLN surgery only identifies the presence of metastases in 50-80% of patients 
who have lymph node metastases [187]. A second surgical procedure is required when 
SLN metastases are identified on permanent histologic analysis in up to 35% of patients 
[188]. Therefore, additional methods to detect lymph node metastases intra-operatively 
have the potential to identify appropriate candidates for axillary dissection and avoid 
false negative events. Other clinical situations in which additional methods to detect 
lymph node metastases would be useful include patients with ductal carcinoma in situ for 
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whom operative removal of the SLN remains controversial or for pre-treatment staging of 
the axilla in patients who are candidates for neoadjuvant chemo- and endocrine therapy. 
Current diagnostic approaches rely on optical imaging of stained cytological or 
histological specimens. Recent advances in optical imaging and optically active contrast 
agents allow high-resolution imaging of cell morphology and tissue architecture in vivo 
without the need for resection [188, 189]. High-resolution fiber optic microscopy 
(HRFM) is a new imaging technology that when used together with a fluorescent contrast 
agent, enables real time visualization of tissue with sub-cellular resolution in vivo. 
Proflavine is a fluorescent dye that stains nuclei [190]. HRFM with proflavine 
application has been investigated as a diagnostic tool to distinguish benign from 
malignant tissue in the oral cavity and esophagus [84, 86]. HRFM with proflavine 
staining has the potential to image cellular morphologic changes that are critical in the 
pathologic evaluation of lymph node metastases by exploiting the cell/nucleus size 
difference between carcinoma and lymphoid cells. Traditional histopathological analysis 
of lymph nodes in breast cancer patients identifies epithelial cell clusters, which are 
enlarged and crowded compared to normal lymphocytes, are hyperchromatic with 
hematoxylin and eosin (H&E) staining, and have an increased nuclear to cytoplasmic 
ratio [191]. In patients who have received preoperative chemotherapy, lymph nodes can 
contain stromal fibrosis and individual tumor cells may be embedded within the fibrosis. 
The goal of this prospective study was to evaluate the potential of HRFM with 
proflavine staining for the detection of lymph node metastases in breast cancer patients. 
While this study was performed ex vivo as a proof of concept, HRFM with proflavine 
staining may eventually be performed in vivo and thus could play an important role in 
83 
clinical management of breast cancer patients, particularly for intra-operative assessment 
of lymph nodes in patients with early disease or for pre-treatment staging of the axilla. 
5.3 Methods 
The high-resolution microendoscope has previously been described in detail [84]. 
The HRFM instrument uses a light emitting diode (LED) with excitation light centered at 
455 nm to excite proflavine fluorescence. A fiber-optic bundle composed of 30,000 
fibers with a center-to-center spacing of approximately four ~m transmits the light and is 
placed in direct contact with the surface to be imaged. The field of view comprises a 
circle that measures 750 ~m in diameter. The system achieves a lateral resolution of 4.4 
~m, sufficient to resolve individual cell nuclei. Figure 5-1 shows an optical diagram of 
the battery-powered HRFM instrument along with a photograph demonstrating the small 
size and portability of the instrument. The system can be assembled for $4,500. 
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Figure 5-1. (a) Optical diagram of the high-resolution microendoscope (b) Photograph 
demonstrating the small size and portability of the battery-powered instrument 
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5.3.1 Clinical Study 
Women 18 and older undergoing surgery for breast cancer that included a SLN 
biopsy followed by complete axillary lymph node dissection were eligible to participate 
in this study. Patients enrolled in this study gave written informed consent to participate, 
and the study was reviewed and approved by the institutional review boards at two 
academic institutions. To comply with HIPAA policies, patient data were labeled by 
accrual number. 
Three to four representative fresh lymph node specimens were taken from each 
patient and prepared for imaging. To ensure that images were taken of areas representing 
normal lymphoid tissue and tumor metastases, a dedicated breast pathologist selected one 
lymph node that was grossly normal and one lymph node that showed gross metastasis. 
Other lymph nodes selected for imaging were grossly ambiguous. For some patients, all 
the lymph nodes appeared normal; in these cases three normal appearing nodes were 
imaged. A dedicated breast pathologist bisected each node to facilitate lymphoid tissue 
1magmg. 
Each lymph node was photographed and imaging sites were marked on the 
photograph to serve as reference points for histopathological correlation. A 0.01% 
solution (w/v) of proflavine hydrochloride (Sigma-Aldrich Corp., St. Louis, MO) was 
topically applied to the cut surface of the lymph nodes for approximately ten seconds. 
The fiber bundle of the HRFM instrument was placed in direct contact with the surface of 
the node for imaging. Multiple images were acquired from adjacent fields of view at 
each location on the specimen by translating the probe position approximately 1 mm. On 
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average, three nodes could be imaged at approximately ten sites within ten to fifteen 
minutes. Following imaging, the nodes were submitted for routine processing and H&E 
staining in specially labeled cassettes to facilitate direct imaging-histopathological 
correlation. A dedicated breast pathologist reviewed the axillary lymph nodes for 
metastases, and the final histopathological diagnosis was used as the gold standard for 
each imaging site. Imaging sites with unequivocal histopathological correlation were 
included in further analysis. 
5.3.2 Image Analysis 
Each image was reviewed to determine that quality control criteria were met. 
Images with motion artifacts or inadequate contact between fiber bundle and tissue were 
excluded from analysis. Each image that passed quality control was analyzed to identify 
quantitative features that could be useful to distinguish normal lymphoid tissue from 
metastases. Because adipose tissue is not useful in this distinction, all images were first 
cropped to remove regions of adipocytes and obtain a rectangular shaped field containing 
nuclei of lymphocytes or tumor cells. The dimensions of this field were variable because 
the region of each image containing nuclei of interest was also variable. A reference 
standard (captured in each image) was used to normalize pixel intensity values of the 
green channel of each corresponding image to account for any potential day-to-day 
variation in the HRFM instrument and to allow comparison between images with 
different exposure times. 
Five image features were calculated from each normalized regton (Matlab, 
Mathworks, CA). These features included: mean image intensity, standard deviation of 
image intensity, skewness, kurtosis, and entropy. Mean image intensity was selected as a 
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feature that may be useful to separate normal lymphoid tissue from metastatic tissue 
because malignant cells crowd together, are enlarged, and are hyperchromatic with H&E 
stain. Since proflavine stains nuclei, images containing malignant cells may have a higher 
intensity than images of normal lymphatic tissue. The remaining four features describe 
variations in pixel intensity throughout the image and were evaluated because the 
disruption of tissue architecture that occurs with metastasis may also alter the distribution 
of pixel intensity values. Standard deviation describes the spread of pixel values relative 
to the mean; high values of standard deviation correspond to a wider image histogram 
with a wide range of pixel intensities. Skewness describes asymmetry of the image 
histogram and indicates if pixel values are concentrated at low or high values. Positive 
skewness on a histogram occurs when there are more low values than high, negative 
skewness when there is a concentration on high values, and zero skewness describes a 
symmetric histogram. Kurtosis describes the peakedness of an image histogram and is 
sensitive to the size of the histogram tails. Entropy is a statistical measure of randomness 
that can be used to characterize the texture of an image. High values of entropy indicate 
greater randomness while low values of entropy result from a more uniform image. Each 
of these investigated features represents an objective, quantitative metric for assessing 
pixel intensity and distribution in an image. 
Since multiple images of adjacent fields of view were obtained at each site in 
order to increase the region surveyed, the feature values calculated for each image were 
grouped by site and then averaged. A one-way ANOV A test was performed to compare 
average feature values from sites containing normal lymphoid tissue and sites containing 
metastases. For each feature, a classification algorithm was developed using linear 
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discriminant analysis to discriminate between normal lymphoid tissue and lymph nodes 
containing metastases, using histology as the gold standard. Because this was a pilot 
study with a relatively small number of measurements, the same data set was used to train 
the algorithm and test its performance. Sensitivity and specificity of classification were 
calculated for each of the five features. A receiver operator characteristic (ROC) curve 
was constructed and the area under the curve (AUC) was recorded. The two features 
with the best individual diagnostic performance were identified, and classification 
performance was also assessed when these two features were used together. 
5.4 Results 
A total of 43 lymph nodes were collected from 14 patients for imaging with 
HRFM; 13 patients had three nodes imaged and one had four nodes imaged. Of the 43 
lymph nodes, 27 were normal and 16 were positive for metastases according to 
histopathology. A total of 126 independent sites were marked for diagnosis; at 105 of 
these sites the image was correlated with the histopathological diagnosis. 242 distinct 
images with adjacent fields of view were collected at these 1 05 sites. Of these images, 
150 were of normal lymphoid tissue and 92 were of sites with metastases. Table 5-1 
shows the distribution of data. 
Table 5-1. Distribution of Collected Data from 43 Axillary Lymph Nodes in 14 Breast 
Cancer Patients 
Axillary Lymph Nodes 
Independent Sites with Histological Diagnosis 
Images from Adjacent Fields of View 
Histologically 
Normal 
27 
71 
150 
Histologically 
Metastatic 
16 
34 
92 
Total 
43 
105 
242 
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Figure 5-2 contains an HRFM image in which both adipose and lymphoid tissue 
are visible (Figure 5-2a). Adipocytes display a characteristic lobular structure, while 
lymphocytes are very small and more densely packed. Figure 5-2b shows the green 
channel of the field that was used to calculate feature values; the region containing 
adipocytes is cropped out. Figure 5-2c is the corresponding histology image. 
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Figure 5-2. (a) High-resolution fiber optic microscopy (HRFM) image taken with from a 
histologically normal lymph node in a region containing both adipocytes and 
lymphocytes after application of proflavine to highlight cell nuclei (b) Green channel of 
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the image after cropping to remove adipocytes; quantitative features were calculated from 
this region (c) Corresponding histology at this site shows a normal lymph node. Capsule 
is thin and unremarkable. Fat surrounds the node. The node is populated with uniform, 
small, round lymphocytes. 
Figure 5-3 illustrates representative results from a set of lymph nodes from a 
single patient. Figure 5-3a shows the photograph of three bisected nodes with eight 
imaging sites marked in blue for subsequent pathologic correlation. After examining the 
corresponding H&E slides, a dedicated breast pathologist determined that the node on the 
left was positive for metastases, with a negative periphery. The node in the middle was 
negative for metastases. Images collected from both of these nodes could be used in 
image analysis because the measurement site could be correlated to a histopathology gold 
standard. The node on the right was determined to be positive with very small subtle 
occasional single tumor cells with no dominant mass. Images from this node were not 
used in further analysis because it was difficult to determine if HRFM measured a site 
containing a few tumor cells or not. Figure 5-3b shows representative HRFM images 
collected at Sites 4 and 7 in the photograph. The HRFM image from site 7 has larger, 
more crowded nuclei and the average image intensity is greater as a result. The HRFM 
image from site 4 has smaller nuclei that are spaced farther apart; the average image 
intensity is lower because the cells are not as densely packed. The corresponding H&E 
images for these sites are shown in Figure 5-3c. The H&E image of site 7 indicates nests 
of tumor cells, while that of site 4 shows a normal node with sinus histiocytosis. Figure 
5-3d depicts the image histograms that were obtained for each field shown in Figure 
5-3b. The red histogram corresponds to the image obtained from site 7 (metastatic), 
while the blue histogram corresponds to the image obtained from site 4 (normal lymphoid 
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tissue). Calculated feature values for each image are indicated. The metastatic site has a 
higher mean intensity than the normal site as seen by the shift in the center of the image 
histogram. Low skewness is noted in the metastatic site, indicating a more symmetrical 
histogram, while high skewness is noted in the normal site as a result of more pixel 
values concentrated at lower intensities with a long tail at higher intensity values. 
Kurtosis is higher for the normal site as seen by the sharp, high peak in the histogram, 
while the histogram of the metastatic site has a broader peak with lower kurtosis. The 
metastatic site has higher entropy, which indicates that the image is more random than 
the normal site. Standard deviation is higher in the metastatic site as seen by the wider 
distribution of pixel values around the mean as compared to the normal site. 
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Figure 5-3. (a) Photograph of three lymph nodes from a single patient with imaging sites 
marked in blue for correlation to pathology (b) HRFM images collected from sites 7 and 
4 with cropped region of interest indicated: site 7 contains metastases while site 4 is 
normal lymphatic tissue (c) Corresponding H&E images for these sites: The image from 
site 7 shows that metastatic carcinoma has replaced part of the lymph node. Dense 
fibrosis surrounds the metastatic tumor cells. Insert shows high power magnification 
( 40X) of tumor cells. The neoplastic cells are arranged in nests and have amphophilic, 
vacuolated cytoplasms and prominent nuclei. The image from site 4 shows a normal 
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lymph node with sinus histiocytosis. The lymph node capsule is thin and the sub-
capsular sinus contains reactive histiocytes. (d) Image histograms from each region of 
interest; site 7 is shown in red while site 4 is shown in blue. Calculated feature values for 
each image are also indicated. 
Figure 5-4 shows box plots of the average feature values for each diagnostic 
category. Red boxes represent feature values from sites containing metastases, while 
blue boxes represent normal sites. All feature values were normalized to the median 
value of the normal lymphoid tissue set in order to show the range of values on a 
consistent scale. P-values from a one-way ANOVA test for each feature are also 
included in Figure 5-4, and the features are listed in order from lowest p-value to highest. 
The average feature values of normal lymphoid tissue are statistically significantly 
different from the feature values of metastatic tissue for all five features (p < 0.05). 
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Figure 5-4. Box plots showing feature values for images separated by diagnostic 
category. Values from images containing normal lymphatic tissue are shown in blue, 
while values from images containing metastases are red. All values are normalized to the 
median value of the normal set in order to show all features on the same scale. P-values 
obtained from a one-way ANOVA test are listed for each feature. 
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Table 5-2 ranks the diagnostic performance of each of the five image features by 
linear discriminant analysis, listed in order from highest to lowest AUC. Mean image 
intensity and skewness were the two highest performing features, each with an AUC of 
0.81. This order of performance is consistent with the p-values for each feature (Figure 
5-4). 
1 
2 
3 
4 
5 
Table 5-2. Feature Performance 
Quantitative Feature 
Mean image intensity 
Skewness 
Kurtosis 
Entropy 
Standard deviation 
Sensitivity 
82% (28/34) 
85% (29/34) 
71% (24/34) 
59% (20/34) 
65% (22/34) 
Specificity 
69% (49/71) 
66% (47/71) 
73% (52/71) 
76% (54/71) 
65% (46/71) 
AUC 
0.81 
0.81 
0.76 
0.70 
0.64 
Figure 5-5 illustrates results when the top performing two individual features, 
mean image intensity and skewness, were combined. Figure 5-5a shows a scatter plot of 
mean intensity versus skewness for each image; both features provide discriminatory 
ability. Figure 5-5b shows the ROC curve for the algorithm developed using both 
features. The resulting AUC improved to 0.84. At the Q-point of the ROC curve, 
sensitivity and specificity with this two-feature algorithm were 79% (27/34) and 77% 
(55/71), respectively. An AUC value of0.85 was obtained when the data were randomly 
divided into training and test groups by patient, with all images from a specific patient 
assigned to either testing or training. This simulates the process of collecting a training 
group to train the algorithm, and then collecting a separate patient set for testing, so it is 
encouraging that the performance is nearly identical to the results obtained when the 
entire data set was used for both training and testing. Although performance of the 
algorithm could improve slightly if all five of the investigated features were used in 
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combination, this would likely result in overtraining of the algorithm due to the small size 
of the data set from this pilot study, and so the algorithm was limited to only two 
combined features. 
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Figure 5-5. (a) Scatter plot by site of mean intensity and skewness: normal sites are 
shown as a blue 'x ' while metastatic sites are shown as a red square. (b) ROC curve 
obtained from a classification algorithm using linear discriminant analysis with both 
mean intensity and skewness as features 
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5.5 Discussion 
This pilot study demonstrates the technical feasibility of ex vivo HRFM with 
proflavine contrast enhanced fluorescence imaging to visualize cell nuclei in axillary 
lymph nodes from breast cancer patients. These preliminary results demonstrate 
encouraging diagnostic potential of this fluorescence molecular imaging modality to 
identify lymph nodes containing metastases. Using the image features of mean intensity 
and skewness, a classification algorithm separating normal lymphoid tissue from tissue 
containing metastases was developed that could achieve an AUC of 0.84. This compares 
with the reported sensitivity and specificity of current standard preoperative sonographic 
methods of evaluating axillary nodes; a recent review of 16 published studies described 
sensitivity ranging between 49-87%, and specificity between 56-97% [192]. One 
comparative advantage of optical imaging is the high resolution, which may make this 
technology more useful for detecting microscopic disease. 
Differences observed in these image features are consistent with qualitative 
differences observed between images from normal lymphoid tissue and metastatic 
regions. Images obtained from metastatic sites appear brighter (higher mean image 
intensity) than images obtained from normal lymphoid tissue. This is due to the enlarged, 
crowded nuclei present in tumor cells, while normal lymphocytes have small nuclei that 
are spaced further apart. Higher mean intensity may also reflect the higher occurrence of 
diploidy and multiploidy and increased genetic material in cancer cells. Because images 
of normal lymph nodes have nuclei that are spaced further apart, there are more dark 
pixels, resulting in a positive skewness. Images of metastatic nodes have fewer low pixel 
values due to crowding and enlargement of nuclei and therefore have lower skewness. 
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Calculations to determine mean intensity and skewness of an image can be performed 
extremely rapidly, potentially allowing a classification prediction in near real time. The 
step of cropping the image is critical for quality control, as acellular regions of fibrosis or 
folding of the tissue were occasionally observed to also display brighter fluorescence 
signal. This demonstrates why the high resolution imaging itself is important; simple 
intensity measurements would not be able to distinguish between tissue types. Though 
choosing a region that contains only nuclei could potentially introduce some user bias, 
this step prevents some false positive results. 
While this pilot study demonstrates encouraging results regarding the technical 
feasibility of HRFM with proflavine to visualize cell nuclei in axillary lymph nodes from 
breast cancer patients and the diagnostic potential of HRFM with proflavine to 
differentiate benign from malignant axillary lymph nodes using quantitative image 
features of mean intensity and skewness, future studies are needed to evaluate the 
diagnostic performance of the imaging method in a larger, independent validation set of 
patients. Additional improvements to this technique include increasing the size of the 
fiber bundle to twice the current diameter, thereby increasing the field of view four-fold. 
Expanding the area that can be optically interrogated could improve the ability to detect 
metastatic cells by more efficiently imaging a lymph node with decreased imaging time. 
Future clinical studies will also attempt to determine the minimum size of metastasis that 
can be detected with this system. 
The prognostic relevance of isolated tumor cells and micrometastases in lymph 
nodes from patients with breast cancer has become a major area of interest in tandem 
with the increased identification of this low volume disease due to the practice of SLN 
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biopsy [193]. There is also heightened interest in the evaluation of the SLNs after 
neoadjuvant chemotherapy, where the proportion ofmicrometastases is reportedly higher, 
and the performance of intraoperative imprint cytology of SLNs is proportionately lower 
[194]. 
Many functional and molecular imaging techniques are being challenged to detect 
metastatic disease at the microscopic level in SLNs [195-197]. Noninvasive, non-
ionizing, and high-resolution mapping of SLNs in conjunction with minimally invasive 
techniques, such as fine needle aspiration biopsy, is currently being investigated in 
multiple active preclinical protocols. While HRFM has good spatial resolution and high 
collection speed using current instrumentation, the current limitation for in vivo HRFM of 
lymph nodes is depth penetration. A potential resolution to this limitation is the in situ 
delivery ofHRFM (i.e. endoscopy via a biopsy needle) for real-time in vivo interrogation 
of lymph nodes that are assessed preoperatively with ultrasound. The additional costs of 
performing imaging and imaging-guided biopsies may be balanced on average by cost 
savings from avoiding SLN evaluations for patients with documented nodal metastases 
preoperatively [ 198]. An aspect of this technique that may limit speed of translation to 
the clinic is the necessary approval process from the United States Food and Drug 
Administration (FDA) to use proflavine in human subjects. However, these pilot studies 
are necessary to provide the foundation for future pursuit of human trials. Optical 
imaging can be performed very rapidly, allowing a large area to be surveyed in a short 
time, making it an attractive technology for this application. An advantage of optical 
imaging over traditional histopathology is that this rapid imaging can be performed in 
vivo. However, the intent of this technology is to augment current standards of care, not 
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to attempt to replace the gold standard of histopathology. The role of HRFM in the future 
may be best suited for intra-operatively identifying candidates for full axillary dissection, 
thus preventing the need for a second surgery in some patients, or for preoperative 
staging of axilla. 
These preliminary results demonstrate the technical feasibility and diagnostic 
potential of quantitative molecular imaging using HRFM with proflavine fluorescent 
staining to discriminate between normal and metastatic axillary lymph nodes ex vivo in 
breast cancer patients. This rapid technique is simple, inexpensive, and can potentially be 
exploited to augment patient care by providing an alternative technique for the detection 
of micrometastases while requiring fewer resources and expertise. 
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CHAPTER 6: MULTIMODAL CONTRAST AGENTS FOR MAGNETIC 
RESONANCE AND OPTICAL IMAGING 
6.1 Abstract 
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Non-invasive imaging plays an important role in both fundamental cancer 
research and clinical management of patients. To exploit the advantages of non-invasive 
imaging as a tool in research and in the clinic, we have developed multimodal contrast 
agents that are functional for both magnetic resonance and optical imaging. Molecularly-
targeted optical imaging is achieved by using an antibody to the epidermal growth factor 
receptor that has been conjugated to an Alexa Fluor 64 7 dye. Gadolinium-based contrast 
agents (Gd-CAs) such as the clinically approved agent Magnevist® and ultra-short 
carbon nanotubes (US-tubes) doped with gadolinium provide enhancement of signal for 
magnetic resonance imaging (MRI). Gd-CAs and antibody-dye conjugates were 
sequentially co-loaded into nanoporous structured silicon microparticles 1.0 micrometers 
in diameter. It has been previously demonstrated that loading Gd-CAs into silicon discs 
increases relaxivity, thus improving sensitivity of detection [ 199]. The loading efficiency 
of the antibody-dye conjugate into these silicon discs with and without Gd-CAs was 
quantified using a fluorometer. The highest loading efficiency of the antibody-dye 
conjugate obtained (27%) was achieved during co-loading with Magnevist(R) in small 
pore size silicon discs. The loading remained variable between samples; the standard 
deviation of cumulative loading in five samples was 47% of the mean. However, the 
optical signal within the silicon discs in all samples was easily visualized using a Zeiss 
100 
LSM 510 Meta Confocal Microscope. Eventually, the biodistribution of this agent in a 
tumor model could be explored for applications in cancer diagnostics and imaging. 
6.2 Introduction 
Non-invasive imaging plays an important role in both fundamental cancer 
research and clinical management of patients. While my previous research focused 
solely on optical imaging, several other types of non-invasive imaging are currently 
utilized in clinical practice. These include magnetic resonance imaging (MRI), positron 
emission tomography (PET), ultrasound (US), computed tomography (CT) and single 
positron emission computed tomography (SPECT). While some of these modalities can 
operate without exogenous contrast agents (MRI, US, CT), incorporation of exogenous 
agents can provide functional information or improve image contrast. Each modality has 
strengths and weaknesses such as the resolution or depth of penetration, so it is important 
to select an appropriate imaging modality for a clinical application [200, 201]. As 
described in the studies presented in previous chapters of this thesis, optical imaging can 
detect signal originating from the surface of tissue or explore deep tissue when an optical 
probe is inserted through a needle. However, it is difficult to apply optical techniques to 
imaging deep tissue because of limits to the depth of photon penetration through tissue. 
In many cases, combining imaging modalities may allow you to draw from the 
strengths of each modality in order to get a better overall assessment of a clinical 
problem. Because of this potential, multimodal imaging is a rapidly growing field [202]. 
In this study, a multimodal contrast agent that is both optically active and improves 
contrast in magnetic resonance imaging is developed and characterized. By combining 
MRI and optical imaging, anatomic information can be obtained from the MRI signal, 
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and high resolution molecular-specific information can be obtained from the optical 
signal. Previously developed multimodal MRI and optical imaging agents have either 
physically conjugated an optical agent to an iron oxide core [203] or gadolinium-based 
compound [204, 205], or encapsulated different MRI and optical probes together within a 
liposome [206]. Physical conjugation results in a co-localized signal from both 
modalities (unless the linker molecule is enzymatically degraded), but agents 
encapsulated together may result in a distinct biodistribution pattern once the liposome or 
other carrier vesicle breaks down. In this study, MRI agents are co-loaded into a silicon 
disc carrier agent along with an optically active antibody. This approach is similar to 
liposomic encapsulation because the two agents are not physically conjugated. This 
study characterizes the efficiency and variability of loading of the antibody-dye conjugate 
into silicon discs and the release of the antibody over time. 
6.3 Materials and Methods 
An antibody to the epidermal growth factor receptor (Baylor College of Medicine 
Monoclonal Antibody Facility, Houston, TX) was conjugated to an Alexa Flour 647 
carboxylic acid, succinimidyl-ester (Invitrogen, Carlsbad, CA). Excess free dye was 
removed using Zeba Spin Desalting columns with a 7 kDa molecular weight cut-off 
(Thermo Scientific Pierce, Rockford, IL). The final concentration of this antibody-dye 
conjugate was 0.83 mg/mL. 
Two different gadolinium-based contrast agents (Gd-CAs) were investigated in 
this study: Magnevist®, a clinically approved Gd3+ polyaminocarboxylate complex, and 
gadonanotubes (GNTs), a nanoscale carbon-based tube structure doped with Gd3+ ions. 
Magnevist® is commercially available (Bayer Healthcare Pharmaceuticals, Wayne, 
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USA), and was used at a loading concentration of 1 mM. GNTs were obtained from Lon 
Wilson's lab in the Chemistry Department at Rice University, and were synthesized as 
described in previous literature [199, 207]. GNTs were used at a loading concentration of 
0.2mM. 
Silicon discs with a diameter of 1 micrometer and height of 0.4 micrometers were 
obtained from Paolo Decuzzi's lab at the Methodist Hospital Research Institute in 
Houston, Texas. Small pore size discs had an average pore diameter of approximately 10 
nanometers, and huge pore size discs had an average pore diameter of around 40 
nanometers. The chemical fabrication of these silicon discs has been described 
previously [199, 208]. 
6.3.1 Co-loading of Silicon Discs 
To load silicon discs with both the magnetically active contrast agent and the 
EGFR-targeted optical imaging agent, the following steps were performed: 
(1) Begin with 108 silicon discs (dry) 
(2) Loading: add 100 ~-tL ofGd-CA 
(3) Sonicate solution for 10 minutes 
( 4) Centrifuge for 1 0 minutes at 1 000 rpm 
(5) Remove supernatant containing free Gd-CAs 
(6) Washing: add 100 ~-tL ofwater 
(7) Centrifuge for 1 0 minutes at 1 000 rpm 
(8) Remove supernatant containing free Gd-CAs 
(9) Repeat steps 2-8 twice for a total of 3 loading and washing steps with Gd-CA 
(1 0) Loading: add 100 !J.L of antibody-dye solution 
(11) Sonicate solution for 1 0 minutes 
(12) Centrifuge for 10 minutes at 1000 rpm 
(13) Remove supernatant containing free antibody-dye 
(14) Washing: add 100 J.lL ofwater 
( 15) Centrifuge for 10 minutes at 1000 rpm 
(16) Remove supernatant containing free antibody-dye 
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(17) Repeat steps 2-8 twice for a total of 3 loading and washing steps with the 
antibody-dye 
(18) Reconstitute sample in 100 J.lL of water or phosphate buffered saline 
(PBS). 
Control samples in which only antibody-dye conjugate was loaded into the silicon 
discs were also prepared. In this case, the steps to load the Gd-CA were skipped (steps 2-
9), but the remaining steps were performed as indicated above. Control samples 
containing only Gd-CA and no optical agent were prepared by ending the previously 
described process after completion of step 9. When Magnevist® was co-loaded into the 
silicon discs with the antibody-dye, the loading steps were combined and equal parts (50 
J.lL each) ofMagnevist® and antibody-dye were added simultaneously to the particles. 
6.3.2 Quantification of Antibody-Dye Loading 
To quantify the efficiency of loading the antibody-dye conjugate into the pores in 
the silicon discs, the supernatant that was removed during the loading and washing steps 
was analyzed in the SPEX Fluorolog-3 fluorometer (Horiba Jobin Yvon Inc., Edison, 
NJ). 10 J.lL of supernatant was diluted in Milli-Q water (Millipore, Billerica, MA) to a 
total volume of 4 mL in a quartz cuvette. The original antibody-dye conjugate was used 
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as a control measurement of fluorescence to which each supernatant sample was 
normalized. Fluorescence intensity at peak emission (670 nm) was used. Based on the 
fraction of antibody-dye remaining in the supernatant as measured in the fluorometer, the 
fraction of antibody-dye that was loaded into the silicon discs could be calculated 
indirectly. The fmal sample containing the loaded silicon discs was also measured 
directly in the fluorometer. 
6.3.3 Confirmation of Antibody-Dye Loading 
To confirm that the optically active antibody-dye conjugate was loaded into the 
pores within the silicon disc, the samples were imaged with a Zeiss LSM 510 Meta 
Confocal Microscope with appropriate excitation and emission filters. 
6.3.4 Monitoring Release of Antibody-Dye Over Time 
The silicon discs used in this study will degrade over time in the presence of salts, 
releasing the optically active component of this multimodal imaging agent. To 
characterize the release of antibody-dye from the silicon discs over time, the samples 
were reconstituted in PBS and placed in an incubator to simulate a physiologically 
relevant environment. At time intervals including 0, 1, 4, 9, 24, 48, and 72 hours, the 
samples were centrifuged and the supernatant was removed and measured in the 
fluorometer as previously described. 1 00 uL of PBS was used to reconstitute the dry 
sample. The sample itself was also measured directly at each time point. An antibody-
dye only control sample kept in the incubator was measured at each time point as a 
fluorescence reference. 
105 
6.4 Results 
6.4.1 Quantification of Antibody-Dye Loading 
Antibody-dye conjugate was co-loaded with Magnevist® in small pore (1 0 nm) 
sized silicon discs as described in the methods above. Based on the indirect method of 
determining efficiency of loading by measuring supernatants, this combination of Gd-CA 
and pore size resulted in 27% of the antibody-dye being incorporated into the silicon 
discs on average (n=5). The indirect method was chosen over the direct measurement of 
the loaded samples due to concerns of dye self-quenching while in close proximity within 
the silicon disc, and also possible quenching of the dye by the Gd-CA. Figure 6-1 shows 
the efficiency of loading by step in each of the five samples. The y-axis in this graph and 
the following graphs is the fraction of antibody that was loaded out of the amount added 
in each step. On average, step 1 loaded 40% of the available antibody-dye with a 
standard deviation that was 55% of the mean, step 2 loaded 14% with a standard 
deviation that was 53% of the mean, and step 3 loaded 26% ofthe available antibody dye 
with a standard deviation that was 63% of the mean. Figure 6-2 shows the average 
loading efficiency per step. 
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Figure 6-2. Average loading efficiency of the antibody-dye by step in small pore sized 
silicon discs co-loaded with Magnevist® 
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When the cumulative efficiency of loading was examined to determine the overall 
variability of loading between different samples, the final variability after step 3 was 4 7% 
of the mean. Figure 6-3 shows the cumulative loading fraction after each step. 
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Figure 6-3. Cumulative fraction of antibody-dye loaded after each step in small pore 
sized silicon discs co-loaded with Magnevist ® 
The antibody-dye conjugate was also loaded into silicon discs with huge size 
pores of about 40 nm in diameter, both alone and with co-loading of GNTs. The 
efficiency of loading in these combinations was just as variable and but less efficient than 
the results shown previously, and will not be detailed in this thesis. 
6.4.2 Confirmation of Antibody-Dye Loading 
Confocal imaging was used to confirm that the multimodal imaging agents were 
optically active as expected. All samples loaded with antibody-dye conjugate were easily 
visualized using the fluorescence microscope, whether or not Gd-CAs were also loaded. 
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Control samples of silicon discs alone or silicon discs with only Gd-CA (Magnevist® or 
GNTs) had no detectable fluorescence signal. Figure 6-4 shows an example image from 
a small pore size silicon disc sample co-loaded with antibody-dye and Magnevist®. 633 
nm laser power was 50% and gain was 450. 
Figure 6-4. Representative fluorescence confocal image of silicon discs loaded with an 
optically active antibody 
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6.4.3 Monitoring Release of Antibody-Dye Over Time 
When a sample was monitored over time to determine the profile of release of the 
antibody-dye component from the silicon discs, it appeared that the majority of antibody 
was released within the first 9 hours. The time-course profile of a representative sample 
is shown in Figure 6-5. Other samples had similar profiles but on a different fluorescence 
intensity scale. This example sample has antibody-dye co-loaded with GNTs in huge 
sized pore silicon discs. 
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Figure 6-5. Fluorescence intensity of sample over time while exposed to physiologically 
relevant conditions, indicates release of optically active component of the multimodal 
imaging agent 
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6.5 Discussion 
These preliminary characterization studies have demonstrated the technical 
feasibility of combining MRI and optical imaging agents by co-loading in nanoporous 
silicon discs. The amount of loading was estimated based on the removed supernatant, 
and loading was confirmed by confocal imaging. It's possible that the amount of loading 
could be overestimated by measuring the supernatant, but this indirect measurement was 
chosen because of the likelihood of dye self-quenching while in close proximity within 
the silicon particle. Additionally, the Gd-CA could cause fluorescence to be quenched. 
GNTs have a broad absorbance spectrum as measured in the Cary 50 UV-Vis 
Spectrophotometer, including in the range of the Alexa Fluor 647 dye's excitation and 
emission. When GNTs were added into the antibody-dye conjugate control and 
measured in the fluorometer, the fluorescence decreased. Therefore, measuring the 
loaded silicon disc sample directly has inherent measurement inaccuracies. 
Although the fluorescence may have been quenched from either dye-dye 
interactions or absorbance of the Gd-CAs, the loaded silicon particles were still easily 
visualized with fluorescence confocal imaging. This result helps confirm the presence of 
the optical agent within the silicon discs, and confirms that the antibody-dye conjugate 
remains optically active. As the antibody is released from the disc, it should retain its 
optical properties as well. 
The time-release profile of the antibody indicates that the majority of the optically 
active component is released within the first 9 hours. Previous results in a rodent tumor 
model have indicated that due to their unique size and shape, the silicon discs used here 
accumulate in the tumor tissue following intravenous injection, likely due to the 
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enhanced permeability and retention (EPR) effect in tumors. The observed time-release 
profile may allow these silicon discs to serve as a carrier for the targeted antibody-dye 
conjugate, locally delivering them near the tumor tissue to decrease the non-tumor-
specific effects of binding to EGFR in other organ sites. Whole body MRI could be used 
to locate the tumor and distant metastases, and guide optical probe positioning, and then 
optical imaging through an inserted probe could be used to obtain molecular-specific 
information about the tumor. Optical imaging could also be performed intra-operatively 
to ensure removal of all tumor tissue and also locate metastases for removal. 
6.6 Future Experiments 
The studies described here have only developed and characterized antibody 
loading in silicon discs, with and without the presence of Gd-CAs. The next steps 
required to achieve the potential applications described in the discussion are to first 
improve the consistency of loading between samples and batches. Altering steps of the 
loading method may result in more consistent or more efficient loading. The loading 
process was originally developed for gadolinium-based contrast agents and may need to 
be altered for an antibody. More sets of samples co-loaded with Magnevist® in small 
pore sized silicon discs could help determine which loading steps could be altered to 
improve loading reproducibility. 
If loading remains consistent, it will be important to confirm the efficiency of 
loading in a way other than by measuring the supernatant. One potential technique could 
be to degrade the silicon discs, dilute the sample so that dye-dye interactions and Gd-CA 
quenching is minimized, and measure this solution in the fluorometer. Confocal imaging 
of this sample could confirm that the silicon discs are degraded; degradation may be 
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achieved by heat or chemical methods. However, the degradation method should not 
affect the structure of the antibody-dye conjugate in a way that affects fluorescence 
intensity. Reconstituting the silicon discs in PBS and leaving them in an incubator for a 
few days should achieve degradation without compromising the chemical integrity of the 
antibody or dye. 
Once the loading amount is confirmed by another method, the multimodal 
imaging agents could be applied in an in vitro setting to ensure that the targeting ability 
of the antibody is still functioning as expected. EGFR positive and negative cell lines 
could be used to demonstrate molecular-specific targeting ability. From discussions with 
Paolo Decuzzi, it appears that these silicon discs will enter cells through endocytosis in a 
non-targeted manner. Therefore, to distinguish molecular-specific targeting from random 
endocytosis, the silicon discs should be exposed to physiologic conditions to release the 
antibody, and this resulting solution could be incubated with EGFR positive and negative 
cell lines over ice to prevent endocytosis. The need to first release the antibody from the 
silicon discs is because the antibody is trapped within the pores and its targeting moiety is 
not exposed, and therefore will not be able to bind to EGFR molecules on the cell 
surface. The cells could be imaged using confocal microscopy to confirm molecular 
specificity. 
Finally, the multimodal 1magmg agent could be intravenously injected into a 
rodent tumor model to examine the biodistribution of the agent, observe if MRI contrast 
of the tumor is enhanced, and determine if optical imaging of EGFR in the tumor can be 
achieved. More time-release studies would be necessary to determine the optimum time 
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frame to image the animal, but the steps described in this section provide a potential 
outline for future experiments using the this new multimodal imaging agent. 
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CHAPTER 7: SUMMARY AND CONCLUSIONS 
7.1 Summary of Results 
This thesis describes how quantitative optical molecular imaging techniques were 
developed and evaluated for multiple applications in the field of oncology. First, 
molecular-specific optical imaging with targeted contrast agents was used to examine 
biomarker expression near the tissue surface for the clinical application of early 
detection, using oral squamous cell carcinoma as a relevant example. Next, optical 
imaging was used to classify lymph nodes from breast cancer patients as either normal or 
metastatic; this applies to the clinical application of staging and would require an optical 
probe to be inserted through a needle to achieve imaging of sub-surface tissue. Finally, 
to address the clinical application of imaging of deeper tissues that may not be 
immediately accessible to optical imaging, a multimodal imaging agent was developed 
that is both optically active and enhances contrast in magnetic resonance imaging. The 
work presented here identifies applications of optical molecular imaging across a broad 
range of problems in oncology, both as a research tool and to enhance the clinical 
management of cancer patients. 
The second chapter provided background on the problem of oral cancer and 
acknowledged the limitations of current detection aids, which motivated the targeted 
imaging studies presented in chapters three and four. Current methods of detection lack 
specificity due to the high prevalence of confounding lesions in the oral cavity. In 
chapter three, EGF-Alexa 647, an imaging agent that specifically targets EGFR, was 
described, validated, and tested in multiple excised human specimens of oral cancer and 
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dysplasia. In widefield fluorescence images of fresh oral tissue diagnosed as moderate or 
severe dysplasia, we observed an average 2.3 fold increase in the fluorescence signal in 
neoplastic tissue as compared to normal tissue. For samples diagnosed as cancer, we 
observed an average 3.8 fold increase in fluorescence signal. 
Chapter four extends the work described in chapter three by examining multiple 
biomarkers in oral tissue. The addition of imaging metabolic activity with 2-NBDG to 
imaging EGFR expression provides another clinically relevant marker of neoplasia. 
Because optical imaging allows separation of signals due to unique spectral properties of 
the dyes, the relationship of one biomarker to another and how each correlates to the 
presence of disease can also be investigated. A classification algorithm was developed 
based on features from fluorescence images from each imaging agent. Including features 
from both agents in the algorithm resulted in better overall performance and a final AUC 
of 0.83. While the classification performance is not extremely high, optical molecular 
imaging may serve as an important research tool to understand the implications of 
biomarker expression, heterogeneity, and co-localization. This may translate into better 
understanding of cancer biology and have implications for clinical management of cancer 
patients or development of targeted therapeutic agents. 
Chapter five applied optical molecular imaging to the clinical setting of patient 
staging. The presence of axillary lymph node metastases is the most important 
prognostic factor for a patient with breast cancer, and determines appropriate adjuvant 
therapy after surgery. Accessing lymph nodes with optical imaging would require 
threading a small diameter optical probe through a needle. Quantitative image analysis 
resulted in a classification algorithm to distinguish normal lymphoid tissue from 
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metastatic tissue with an AUC of 0.84. The ability to recognize metastatic nodes in vivo 
with optical imaging would identify affected nodes for removal, while allowing normal 
nodes to remain, thus reducing the side effects common in full axillary dissection. 
Chapter six described preliminary results from a project that augments the 
information obtained from optical imaging by combining it with magnetic resonance 
imaging through the development of a multimodal imaging agent. High efficiency, 
consistent loading of the antibody-dye conjugate was achieved in small pore size silicon 
discs co-loaded with Magnevist. This imaging agent could be used for imaging of deep 
tissue, since MRI is able to achieve full body contrast. After using MRI to identify the 
location of a tumor, an optical probe could be guided to the appropriate location to obtain 
high resolution, molecular-specific information. Combining optical imaging with other 
modalities may extend its usefulness as both a cancer research tool and clinically relevant 
technique. 
7.2 Future Directions 
The studies presented in this thesis lay the groundwork for optical molecular 
imaging in several different settings by presenting proof of concept design and ex vivo 
experiments with human tissue. The eventual goal of all of these projects, however, is to 
perform optical molecular imaging in vivo to gain knowledge about an individual 
patient's neoplasia and more effectively tailor diagnosis and treatment options. This type 
of personalized medicine may result in better outcomes for individuals affected by cancer 
by improving early diagnosis, determining extent of tumor spread so ideal surgical 
resection is achieved, or understanding which subset of patients will respond to a 
particular therapy. 
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Some progress has already be made to move this type of research from ex vivo to 
in vivo, for example, in 2008, Thomas Wang's group at Stanford reported the in vivo use 
of a targeted optical imaging agent for the detection of dysplasic colonocytes [209]. In 
this case, a heptapeptide selected through phage display and panning with excised tissue 
was conjugated to fluorescein and applied topically through the instrument channel in a 
standard colonoscope. A few lessons can be learned from this example. First, 
fluorescein was used as the dye because it is already FDA approved for in vivo use, 
which likely aided the approval by the Stanford IRB. Unfortunately, fluorescein's 
excitation and emission occur within the same wavelengths as in vivo autofluorescence. 
Another dye that is FDA approved for in vivo use, indocyanine green (ICG), has spectral 
features in the near infrared, which are less likely to overlap with tissue autofluorescence. 
However, the lack of a multitude of approved optical dyes currently limits the in vivo use 
of multiplexed optical imaging, and is something that will need to be addressed for 
optical molecular imaging to reach its full clinical potential. This will require in vivo 
toxicity studies in animals and humans before new dyes can be approved. 
An aspect of the heptapeptide study that is encouraging for future extension of the 
research presented in this thesis is the effective transition of the targeting ability of the 
imaging agent from ex vivo, resected colonic tissue to in vivo, intact colons. The peptide 
was selected for its high affinity to dysplastic colon tissue during sequential panning 
studies, and the same peptide was able to effectively target dysplastic colonocytes in vivo 
as well. The research presented here is based on ex vivo studies, with the hope that ex 
vivo results will translate to in vivo situations, and this study provides one encouraging 
example that ex vivo tissue is a good model for future in vivo work. 
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2-NBDG, one of the imaging agents used in the studies in resected oral mucosa, 
provides a way to monitor metabolic activity of tissue. While this agent still shows 
contrast in freshly resected tissue, using it in vivo may only enhance its ability to detect 
metabolic activity due to neoplasia. In vivo, the tissue will still be connected to 
vasculature that will supply nutrients and keep the tissue viable, but after the tissue has 
been removed, it lacks support and the cells will quickly die. The EGFR-targeted 
imaging agents may also result in improved optical contrast in vivo, where active cells 
will internalize the EGF receptors along with the imaging agent and therefore continually 
accumulate optical signal within the cytoplasm. In vivo tests will of course have to be 
conducted to determine if this is the case, but it seems unlikely that in vivo tissue would 
have decreased optical contrast from ex vivo tissue. 
A very recent study has implications for the research presented in this thesis 
related to staging in breast cancer. In February of this year, a phase 3 noninferiority trial 
was published in the Journal of the American Medical Association comparing overall and 
disease-free survival in breast cancer patients with sentinel lymph node metastases who 
did or did not undergo full axillary dissection [210]. The nearly 1000 patients included in 
this study had breast tumors less than five centimeters in diameter that were removed 
with lumpectomy that achieved clear margins. The patients all had positive sentinel 
lymph nodes (between one and three positive SLNs), with "micrometastases" less than 
two millimeters in diameter. All patients also received radiation therapy. The study 
observed no significant difference in five-year disease-free or overall survival, indicating 
that full axillary dissection may not be required for patients who have small tumors, 
achieve good surgical results, and have only micrometastases in the sentinel node. Due 
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to the side effects associated with full axillary dissection, clear guidelines of which 
patients may or may not benefit from additional removal of lymph nodes will help 
prevent unnecessary adverse effects while still achieving maximal survival benefits. 
After the pilot study of using HRFM with proflavine contrast demonstrated the 
technical feasibility of detecting lymph node metastases with optical imaging techniques, 
planning for future studies with HRFM centered around the goal of determining the size 
limit of metastases that could be detected. However, in light of this recently published 
study, improving the size limit of nodal metastases detection may not be the best 
direction for the project. The diameter of the optical probe used in the pilot study was 
750 micrometers, which is below the two millimeter cut-off size used in the 
noninferiority study. Instead, HRFM could potentially be used to measure metastasis size 
to see if nodal metastases are above or below two millimeters in diameter to determine if 
full axillary dissection is necessary. Staging of axilla could be performed preoperatively 
through a needle as an adjunct to fine needle aspiration, or intraoperatively. 
The studies described in this thesis demonstrate the potential benefit of optical 
molecular imaging in a variety of clinical settings. While future in vivo toxicity tests will 
be required to move these imaging agents from ex vivo tissue to patients, these studies 
help validate targeting ability of the imaging agents and suggest roles for optical 
molecular imaging as both a research tool and in clinical management of cancer patients. 
Translation of these imaging agents and techniques to the clinic may result in improved 
survival and personalized patient care. 
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